| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D, Inc. | <1 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | <1 mi |
| Galleri® in the Medicare Population. | N/A | GRAIL, Inc. | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| SBRT Boost for Unfavorable Prostate Cancer' | N/A | MemorialCare Health System | <1 mi |
| SuperSaturated Oxygen Comprehensive Observational Registry | — | TherOx | <1 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | <1 mi |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Multicenter Prospective Observational Cohort Study Evaluating the Impact of Cancer-Directed Treatment and Medication Use, Including Cannabis Use, in Multiple Myeloma Patients | — | City of Hope Medical Center | <1 mi |
| Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients | N/A | City of Hope Medical Center | <1 mi |
| A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer | — | Cedars-Sinai Medical Center | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers | N/A | City of Hope Medical Center | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | <1 mi |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | Phase 4 | Regeneron Pharmaceuticals | <1 mi |
| A Study to Evaluate Solriktug in Adult Participants With Asthma | Phase 2 | Uniquity One (UNI) | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Phase 3 | Pfizer | <1 mi |
| Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | <1 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection | Phase 1 | GigaGen, Inc. | <1 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Phase 2/3 | Bluejay Therapeutics, Inc. | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | <1 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | Phase 3 | NRG Oncology | <1 mi |
| Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | Phase 2 | City of Hope Medical Center | <1 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Phase 3 | Amgen | <1 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | <1 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | <1 mi |
| Metronomic Therapy for Pediatric Patients With Solid Tumors at High Risk of Recurrence | Early 1 | Miller Children's & Women's Hospital Long Beach | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | <1 mi |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Immediate Postpartum Glucose Tolerance Testing | — | MemorialCare Health System | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | <1 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics | <1 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| RESPONDER-HF Trial | N/A | Corvia Medical | <1 mi |
| Ultrafiltration Versus IV Diuretics in Worsening Heart Failure | N/A | Nuwellis, Inc. | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | <1 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | <1 mi |
| The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial | Phase 4 | VA Office of Research and Development | <1 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR | N/A | Cardiac Dimensions, Inc. | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Phase 2 | Sanofi | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma | Phase 3 | AstraZeneca | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | Phase 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | <1 mi |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | <1 mi |
| Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study | N/A | Stanford University | <1 mi |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | Phase 4 | GlaxoSmithKline | <1 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | N/A | VA Office of Research and Development | <1 mi |
| EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer | Phase 1/2 | VA Office of Research and Development | <1 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | <1 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer | N/A | VA Office of Research and Development | <1 mi |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | <1 mi |
| U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer | Phase 1 | Daiichi Sankyo | <1 mi |
| EXoPERT EMERALD Clinical Study | — | EXoPERT | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine | N/A | Southern California Institute for Research and Education | <1 mi |
| Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) | N/A | VA Office of Research and Development | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment | Phase 1 | Gilead Sciences | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | 6 mi |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | 6 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | 6 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | 6 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | 6 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | 6 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | 6 mi |
| An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study | — | University of Rochester NCORP Research Base | 6 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | 6 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | 6 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | 6 mi |
| Mobile Health for Adherence in Breast Cancer Patients | N/A | ECOG-ACRIN Cancer Research Group | 6 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 6 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | 6 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | 6 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | 7 mi |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | Phase 1 | AVEO Pharmaceuticals, Inc. | 7 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics | 7 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | 7 mi |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Phase 2 | Coherus Oncology, Inc. | 7 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | 7 mi |
| Mechanism(s) of Airflow Limitation During Exacerbation of Asthma | Phase 4 | Gelb, Arthur F., M.D. | 7 mi |
| Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma | — | Gelb, Arthur F., M.D. | 7 mi |
| Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap | — | Gelb, Arthur F., M.D. | 7 mi |
| Congenital Muscle Disease Study of Patient and Family Reported Medical Information | — | Cure CMD | 7 mi |
| Aleniglipron Phase 2 in Type 2 Diabetes Mellitus | Phase 2 | Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics | 7 mi |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Phase 2 | Upstream Bio Inc. | 7 mi |
| Different Doses of Naronapride Vs. Placebo in Gastroparesis | Phase 2 | Dr. Falk Pharma GmbH | 7 mi |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | 7 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | 7 mi |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Phase 2 | Eli Lilly and Company | 7 mi |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Karyopharm Therapeutics Inc | 7 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | 7 mi |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Phase 3 | BeiGene | 7 mi |
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | Phase 3 | AstraZeneca | 7 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | 7 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | 7 mi |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | 7 mi |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | 7 mi |
| A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | Phase 2 | Lantern Pharma Inc. | 7 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | 7 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | 7 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | 7 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | 7 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | 7 mi |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | 7 mi |
| A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed | Phase 1/2 | GlaxoSmithKline | 7 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | 7 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | 7 mi |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | Phase 3 | Merck Sharp & Dohme LLC | 7 mi |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Phase 3 | Shanghai Henlius Biotech | 7 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | 7 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | 7 mi |
| Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | Phase 1 | Lantern Pharma Inc. | 7 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | 7 mi |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Phase 2 | Merck Sharp & Dohme LLC | 7 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | 7 mi |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | Janssen Research & Development, LLC | 7 mi |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Phase 1 | Eli Lilly and Company | 7 mi |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Phase 3 | Novo Nordisk A/S | 7 mi |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Phase 2 | Artiva Biotherapeutics, Inc. | 7 mi |
| A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease | Phase 1 | Eli Lilly and Company | 7 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | 7 mi |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | 7 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | 7 mi |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | Phase 2 | Jonsson Comprehensive Cancer Center | 7 mi |
| Study of LP-184 in Patients With Advanced Solid Tumors | Phase 1/2 | Lantern Pharma Inc. | 7 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | 7 mi |
| Tempus Sculptor Study: Small Cell Lung Cancer (SCLC) Observational Study | — | Tempus AI | 7 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | 7 mi |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Phase 1/2 | Xencor, Inc. | 7 mi |
| A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | Phase 1 | Shanghai Henlius Biotech | 7 mi |
| ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase 3 | ImmunityBio, Inc. | 7 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 7 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | 9 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | 9 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | 9 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 9 mi |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | 9 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | 9 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | 9 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | 9 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | 9 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | 9 mi |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Phase 3 | Xenon Pharmaceuticals Inc. | 9 mi |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | Phase 3 | VistaGen Therapeutics, Inc. | 9 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | 9 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | 9 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | 9 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Phase 3 | Xenon Pharmaceuticals Inc. | 9 mi |
| A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Phase 3 | GlaxoSmithKline | 10 mi |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma | Phase 2 | Eli Lilly and Company | 10 mi |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | 10 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 10 mi |
| A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | Phase 1/2 | Metsera, a wholly owned subsidiary of Pfizer | 10 mi |
| Study to Evaluate Safety, Tolerability and Pharmacokinetics of IDB-011 | Phase 1 | IDBiologics, Inc. | 10 mi |
| Product Surveillance Registry | — | Medtronic | 10 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | 10 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 10 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | 10 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | 10 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | 10 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Phase 3 | AstraZeneca | 10 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | 10 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | 10 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | 10 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | 10 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | 10 mi |
| Study of JK07 in Patients With Chronic Heart Failure | Phase 2 | Salubris Biotherapeutics Inc | 10 mi |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | Phase 3 | National Cancer Institute (NCI) | 10 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | 10 mi |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | ImmunityBio, Inc. | 10 mi |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | 10 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | 10 mi |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Phase 3 | SOFIE | 10 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | 10 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | 10 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | 10 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | 10 mi |
| Ultra-hypofractionated Whole Breast Irradiation With Lumpectomy Cavity Boost for the Treatment of Stage I-III Breast Cancer | Phase 2 | City of Hope Medical Center | 10 mi |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | Phase 3 | NRG Oncology | 10 mi |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Phase 2 | Protara Therapeutics | 10 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | 10 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | 10 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | 10 mi |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | 10 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | 10 mi |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 3 | Loxo Oncology, Inc. | 10 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Phase 3 | Bristol-Myers Squibb | 10 mi |
| A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | Phase 3 | Paradigm Biopharmaceuticals Ltd. | 10 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | 10 mi |
| First in Human Study of UCT-03-008 in Participants With Advanced Solid Tumors | Phase 1 | 1200 Pharma, LLC | 10 mi |
| Clinical Study To Further Evaluate The Efficacy Of Dabrafenib Plus Trametinib In Patients With Rare BRAF V600E Mutation-Positive Unresectable or Metastatic Solid Tumors | — | Novartis Pharmaceuticals | 10 mi |
| Using CircuLating Tumor DNA to Risk Adapt Post-Operative Therapy for HPV-associated Oropharyngeal Cancer | Phase 2 | Zachary Zumsteg | 10 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | 10 mi |
| A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 2 | Hoffmann-La Roche | 10 mi |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | 10 mi |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) | Phase 2 | Merck Sharp & Dohme LLC | 10 mi |
| Starting Technology in At Risk Type 1 Diabetes Study | N/A | University of California, Los Angeles | 10 mi |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | 10 mi |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase 3 | Tenax Therapeutics, Inc. | 10 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | 10 mi |
| Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Phase 2 | Abcentra | 10 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | 10 mi |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | 10 mi |
| POLARx Post Approval Study (POLARx PAS) | N/A | Boston Scientific Corporation | 10 mi |
| Reducing Blood Pressure in Patients With High Cardiovascular Risk | N/A | University of Southern California | 10 mi |
| A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | N/A | Cleerly, Inc. | 10 mi |
| Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT | Phase 4 | Matthew J. Budoff | 10 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | 10 mi |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) | Phase 3 | AstraZeneca | 10 mi |
| SakuraBead Used as Resorbable Embolic for Genicular Artery Embolization | N/A | CrannMed | 10 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Phase 3 | Definium Therapeutics US, Inc. | 10 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | 10 mi |
| Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer | Phase 2 | Cedars-Sinai Medical Center | 10 mi |
| Tart Cherry and Omega-3's for Aromatase Inhibitor Musculoskeletal Symptoms | Early 1 | Philip Chang | 10 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | 10 mi |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | 10 mi |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | 10 mi |
| Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer | Phase 1 | Karen Reckamp, MD, MS | 10 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | 10 mi |
| A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | Phase 1 | TORL Biotherapeutics, LLC | 10 mi |
| First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 10 mi |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Phase 3 | Summit Therapeutics | 10 mi |
| Study to Evaluate the Pharmacokinetics and Safety of Pralatrexate in Patients With Advanced Solid Tumor or Hematological Malignancy and Either Normal Hepatic Function or Mild, Moderate, or Severe Hepatic Impairment | Phase 1 | Acrotech Biopharma Inc. | 10 mi |
| A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2/3 | Karyopharm Therapeutics Inc | 10 mi |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Phase 3 | Epizyme, Inc. | 10 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | 10 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | 10 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 10 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | 10 mi |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | AbbVie | 10 mi |
| Nipocalimab in Moderate to Severe Sjogren's Disease | Phase 3 | Janssen Research & Development, LLC | 10 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | 10 mi |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Phase 3 | AstraZeneca | 10 mi |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Phase 3 | Novartis Pharmaceuticals | 10 mi |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Phase 2 | Merck Sharp & Dohme LLC | 10 mi |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Phase 3 | Bristol-Myers Squibb | 10 mi |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Phase 3 | Novartis Pharmaceuticals | 10 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | 11 mi |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | Phase 4 | Sanofi | 11 mi |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | Phase 2 | Upstream Bio Inc. | 11 mi |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) | Phase 1 | ADC Therapeutics S.A. | 11 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | 11 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | 12 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | 12 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | 12 mi |
| Smart Boot Use to Measure Offloading Adherence | Phase 2 | University of Southern California | 12 mi |
| Evaluating a Lifestyle Intervention to Prevent Recurrence of Diabetic Foot Ulcers | N/A | University of Southern California | 12 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | 13 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | 13 mi |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | 13 mi |
| Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | National Cancer Institute (NCI) | 13 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | 14 mi |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | 14 mi |
| 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee | Phase 2 | OrthoTrophix, Inc | 14 mi |
| L-Theanine to Support Relaxation and Mood for Cancer Patients in Surveillance | Early 1 | City of Hope Medical Center | 14 mi |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | 14 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | 14 mi |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Phase 3 | Eli Lilly and Company | 14 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | 14 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 14 mi |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Phase 2 | Regeneron Pharmaceuticals | 14 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | 14 mi |
| Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis | Phase 2 | AbbVie | 14 mi |
| A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | Phase 4 | Janssen Research & Development, LLC | 14 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee | Phase 3 | Eli Lilly and Company | 14 mi |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Phase 2 | AbbVie | 14 mi |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Phase 2 | Eli Lilly and Company | 14 mi |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Phase 4 | Eli Lilly and Company | 14 mi |
| A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Phase 2 | Pacira Pharmaceuticals, Inc | 14 mi |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Phase 1 | Boehringer Ingelheim | 14 mi |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | AbbVie | 14 mi |
| First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations | Phase 1/2 | Pierre Fabre Medicament | 14 mi |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase 3 | Disc Medicine, Inc | 14 mi |
| Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) | Phase 3 | AstraZeneca | 14 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | 14 mi |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | 14 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | 14 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | 14 mi |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | Phase 2 | Dogwood Therapeutics Inc. | 14 mi |
| Umbrella Study for Analysis of Data Related to Patients With Cancer | — | Tempus AI | 14 mi |
| A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | Pfizer | 14 mi |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 14 mi |
| A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. | Phase 3 | Pfizer | 14 mi |
| A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Phase 1 | Oncotherapeutics | 14 mi |
| Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 | Phase 1/2 | Pathos AI, Inc. | 14 mi |
| Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays | — | Tempus AI | 14 mi |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | 14 mi |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | Phase 4 | Neurocrine Biosciences | 14 mi |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | 14 mi |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 14 mi |
| Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis | Phase 3 | Sun Pharmaceutical Industries Limited | 14 mi |
| A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | Phase 3 | UCB Biopharma SRL | 14 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | 14 mi |
| A Study of Buntanetap in Participants With PD | Phase 2/3 | Annovis Bio Inc. | 14 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | AstraZeneca | 14 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | 14 mi |
| A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment. | Phase 3 | Pfizer | 14 mi |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | 14 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | 14 mi |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Phase 3 | AstraZeneca | 14 mi |
| IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed | Phase 3 | Fortvita Biologics (USA)Inc. | 14 mi |
| Development and Analysis of a Stool Bank for Cancer Patients | — | Persephone Biosciences | 14 mi |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | 14 mi |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Phase 2 | Mirati Therapeutics Inc. | 14 mi |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | AstraZeneca | 14 mi |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | 14 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | 14 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | 14 mi |
| Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment | — | Fresenius Kabi | 14 mi |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase 2/3 | ACADIA Pharmaceuticals Inc. | 15 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Phase 2 | Intra-Cellular Therapies, Inc. | 15 mi |
| Shield Post-Approval Study Protocol | — | Guardant Health, Inc. | 15 mi |
| A Study to Explore the Effect of SP-624 on Brain Network Analytics in Healthy Adults and Adults With Major Depression | Phase 1 | Sirtsei Pharmaceuticals, Inc. | 15 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | 15 mi |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 15 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | 15 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | 15 mi |
| A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study) | Phase 2 | Seaport Therapeutics | 15 mi |
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Phase 2 | Aligos Therapeutics | 15 mi |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Phase 3 | Viatris Innovation GmbH | 15 mi |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Phase 2 | Zenas BioPharma (USA), LLC | 15 mi |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 16 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | 16 mi |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | AstraZeneca | 16 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | 16 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | 16 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | 16 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Phase 3 | AstraZeneca | 16 mi |
| N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma | Phase 2 | ImmunityBio, Inc. | 16 mi |
| A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Combination With Gemcitabine In Participants With Recurrent Platinum-Resistant High-Grade Ovarian Cancer | Phase 2 | ImmunityBio, Inc. | 16 mi |
| A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer | Phase 1/2 | Engeneic Pty Limited | 16 mi |
| Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmocodynamics and Preliminary Antitumor Activity of AT-1965 in Patients With Advanced, Refractory or Recurrent Solid Tumors | Phase 1/2 | Alyssum Therapeutics | 16 mi |
| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Phase 3 | Suven Life Sciences Limited | 17 mi |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Phase 2 | MapLight Therapeutics | 17 mi |
| Stool Sample Collection Study | — | Innovis LLC | 17 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 17 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | 17 mi |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Phase 3 | Intra-Cellular Therapies, Inc. | 17 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | 17 mi |
| A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 | Phase 1 | Alzheimer's Disease Expert Lab (ADEL), Inc. | 17 mi |
| A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities | Phase 2 | Verdiva Bio Dev Limited | 17 mi |
| A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma | Phase 1 | Pfizer | 17 mi |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Phase 3 | Gilead Sciences | 17 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | 17 mi |
| Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus | Phase 1/2 | Gilead Sciences | 17 mi |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | 17 mi |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | 17 mi |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | 17 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | 17 mi |
| A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors | Phase 1 | Bristol-Myers Squibb | 17 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | 17 mi |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | NovoCure GmbH | 17 mi |
| Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | Phase 1/2 | Synthekine | 17 mi |
| A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease | Phase 1 | Fate Therapeutics | 17 mi |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Phase 2/3 | BicycleTx Limited | 17 mi |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | Phase 3 | Novartis Pharmaceuticals | 17 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | 17 mi |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Phase 3 | Amgen | 17 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | 17 mi |
| Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | Phase 1/2 | Georgiamune Inc | 17 mi |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Phase 2/3 | Bristol-Myers Squibb | 17 mi |
| A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer | Phase 3 | Amgen | 17 mi |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | 17 mi |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | AbbVie | 17 mi |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | Phase 3 | Novartis Pharmaceuticals | 17 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Phase 2 | AbbVie | 17 mi |
| A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer | Phase 3 | Janssen Research & Development, LLC | 17 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | 17 mi |
| Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Phase 2/3 | Panbela Therapeutics, Inc. | 17 mi |
| Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | Phase 2 | NATCO Pharma Ltd. | 17 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | 17 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | 17 mi |
| First in Human Study of TORL-1-23 in Participants With Advanced Cancer | Phase 1 | TORL Biotherapeutics, LLC | 17 mi |
| Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Amgen | 17 mi |
| A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) | Phase 3 | Daiichi Sankyo | 17 mi |
| High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy | Phase 4 | Retina Consultants of Orange County | 17 mi |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Phase 3 | Hoffmann-La Roche | 17 mi |
| Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE Participants | Phase 1 | AstraZeneca | 17 mi |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Phase 3 | Novartis Pharmaceuticals | 17 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | 17 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | 17 mi |
| A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors | Phase 2 | AstraZeneca | 17 mi |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | 17 mi |
| Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC. | Phase 1/2 | Chipscreen Biosciences, Ltd. | 17 mi |
| A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | 17 mi |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | 17 mi |
| Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer | N/A | Stanford University | 17 mi |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | Phase 1/2 | AbbVie | 17 mi |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Phase 3 | Pfizer | 17 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | 17 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | 17 mi |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | Phase 1 | UCB Biopharma SRL | 17 mi |
| Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations | Phase 3 | Daiichi Sankyo | 17 mi |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Phase 2/3 | Merck Sharp & Dohme LLC | 17 mi |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | Phase 3 | Bayer | 17 mi |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | 17 mi |
| Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | Phase 3 | Eleison Pharmaceuticals LLC. | 17 mi |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Zenith Epigenetics | 17 mi |
| The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | Phase 1/2 | AVM Biotechnology Inc | 17 mi |
| TEMPUS ARIES: A Biobank Registry Platform Study in Oncology | — | Tempus AI | 17 mi |
| A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment | — | Daiichi Sankyo | 17 mi |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | Phase 3 | BeOne Medicines | 17 mi |
| Study of GS-0151 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | 17 mi |
| PREDICT Therapy Selection for JAK, T-cell, or IL-6 Inhibitor Therapies Using a Molecular Signature Response Classifier (PREDICT) | — | Scipher Medicine | 17 mi |
| A Study of SPY072 in Rheumatic Disease | Phase 2 | Spyre Therapeutics, Inc. | 17 mi |
| ConsideRAte Study - Splenic Stimulation for RA | N/A | Galvani Bioelectronics | 17 mi |
| A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Phase 2 | GlaxoSmithKline | 17 mi |
| Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies | — | Tempus AI | 17 mi |
| A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) | Phase 3 | Amgen | 17 mi |
| A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02) | Phase 2 | Daiichi Sankyo | 17 mi |
| 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Phase 3 | Clarity Pharmaceuticals Ltd | 17 mi |
| A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | Phase 2 | Debiopharm International SA | 17 mi |
| Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 | SWOG Cancer Research Network | 18 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | 18 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | 18 mi |
| Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | Phase 2 | University of Arizona | 18 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | 18 mi |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | Phase 1 | National Cancer Institute (NCI) | 18 mi |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Phase 2 | AstraZeneca | 18 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) | Phase 1/2 | Hoffmann-La Roche | 18 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | 19 mi |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Sanofi | 19 mi |
| A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 19 mi |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | AbbVie | 19 mi |
| Pancreatic Cancer Detection Consortium | — | City of Hope Medical Center | 19 mi |
| Testing Olaparib in Patients With Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer and Other Genitourinary Tumors With DNA-Repair Genetic Changes | Phase 2 | National Cancer Institute (NCI) | 19 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | 19 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | Phase 1/2 | Shenzhen Ionova Life Sciences Co., Ltd. | 19 mi |
| A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | Phase 2/3 | Linnaeus Therapeutics, Inc. | 19 mi |
| First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 19 mi |
| PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | PanTher Therapeutics | 19 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | 19 mi |
| Isunakinra Alone and in Combination With Pembrolizumab in Patients With Colorectal Cancer (MSS) | Phase 2 | Buzzard Pharmaceuticals | 19 mi |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Phase 3 | Genelux Corporation | 19 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | 19 mi |
| Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer | Phase 2 | National Cancer Institute (NCI) | 19 mi |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | 19 mi |
| NP-G2-044 as Monotherapy and Combination Therapy in Patients With Advanced or Metastatic Solid Tumor Malignancies | Phase 1/2 | Novita Pharmaceuticals, Inc. | 19 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | 19 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | 19 mi |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | Pfizer | 19 mi |
| Study of CHS-114 in Participants With Advanced Solid Tumors | Phase 1 | Coherus Oncology, Inc. | 19 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | 19 mi |
| A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC | Phase 2 | Genentech, Inc. | 19 mi |
| Testing Nivolumab and Ipilimumab Immunotherapy With or Without the Targeted Drug Cabozantinib in Recurrent, Metastatic, or Incurable Nasopharyngeal Cancer | Phase 2 | National Cancer Institute (NCI) | 19 mi |
| A Study of DSP-5336 in Relapsed/Refractory AML/ ALL With or Without MLL Rearrangement or NPM1 Mutation | Phase 1/2 | Sumitomo Pharma America, Inc. | 19 mi |
| Mobile Health Intervention to Improve Adherence to Oral Anticancer Therapy | N/A | University of California, Irvine | 19 mi |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase 1 | Acrivon Therapeutics | 19 mi |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | 19 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Phase 3 | Merck Sharp & Dohme LLC | 19 mi |
| SLV-324 Treatment of Metastatic Solid Tumors | Phase 1 | Solve Therapeutics | 19 mi |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Phase 2 | Vyriad, Inc. | 19 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | 19 mi |
| Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma | Phase 1 | Aivita Biomedical, Inc. | 19 mi |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase 2 | Hoffmann-La Roche | 19 mi |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | Phase 3 | AstraZeneca | 19 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | 19 mi |
| A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors | Phase 1 | Daiichi Sankyo | 19 mi |
| Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tumors, The ComBET Trial | Phase 2 | National Cancer Institute (NCI) | 19 mi |
| Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies | Phase 1/2 | Effector Therapeutics | 19 mi |
| A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors | Phase 1/2 | Crinetics Pharmaceuticals Inc. | 19 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | 19 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | 19 mi |
| Autologous Activated Adipose-derived Stem Cells (RB-ADSC) Injected Directly Into the Brain for Mild to Moderate Alzheimer's Disease | Phase 1 | Regeneration Biomedical, Inc. | 19 mi |
| ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves | N/A | Edwards Lifesciences | 19 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | 19 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | 19 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | 19 mi |
| ASCEND CSP IDE Study | N/A | Abbott Medical Devices | 19 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | 19 mi |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma | Phase 2 | Pfizer | 19 mi |
| A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis | Phase 2/3 | Nature Cell Co. Ltd. | 19 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | 19 mi |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 | Vanda Pharmaceuticals | 19 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 19 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | 19 mi |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | Phase 3 | Sanofi | 19 mi |
| A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor. | Phase 1/2 | Novartis Pharmaceuticals | 19 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | 19 mi |
| Perioperative Mindfulness Proposal | N/A | Hoag Memorial Hospital Presbyterian | 19 mi |
| Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029) | Phase 2 | Merck Sharp & Dohme LLC | 19 mi |
| SLV-154 Treatment of Metastatic Solid Tumors | Phase 1 | Solve Therapeutics | 19 mi |
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer | Phase 1 | OnKure, Inc. | 19 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | 19 mi |
| IKS014 in Advanced Solid Tumors That Express HER2 | Phase 1 | Iksuda Therapeutics Ltd. | 19 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | 19 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | 19 mi |
| BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer | Phase 1 | BeOne Medicines | 19 mi |
| A Validation Study to Determine Concordance of Liquid Biopsy and Breast Cancer Diagnosis | — | University of Southern California | 19 mi |
| [177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer | Phase 1 | Novartis Pharmaceuticals | 19 mi |
| Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors | Phase 1/2 | Ensem Therapeutics | 19 mi |
| Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | Phase 1 | National Cancer Institute (NCI) | 19 mi |
| Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | Phase 1 | AstraZeneca | 19 mi |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | 19 mi |
| Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors | Phase 2 | Aadi Bioscience, Inc. | 19 mi |
| A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 19 mi |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | 19 mi |
| Testing of Tazemetostat in Combination With Topotecan and Pembrolizumab in Patients With Recurrent Small Cell Lung Cancer | Phase 1 | National Cancer Institute (NCI) | 19 mi |
| A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Bristol-Myers Squibb | 19 mi |
| A Phase 1 Study of LNCB74 in Advanced Solid Tumors | Phase 1 | NextCure, Inc. | 19 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 19 mi |
| A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | 19 mi |
| A Study of KK2269 in Adult Participants With Solid Tumors | Phase 1 | Kyowa Kirin Co., Ltd. | 19 mi |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Phase 1/2 | Daiichi Sankyo | 19 mi |
| Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | Phase 1 | Abdera Therapeutics Inc. | 19 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | 19 mi |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Phase 1/2 | Volastra Therapeutics, Inc. | 19 mi |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase 1 | IDEAYA Biosciences | 19 mi |
| Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/2 | Monte Rosa Therapeutics, Inc | 19 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | 19 mi |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Phase 1 | AstraZeneca | 19 mi |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Phase 3 | Merck Sharp & Dohme LLC | 19 mi |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Phase 1 | BeiGene | 19 mi |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Phase 3 | Merck Sharp & Dohme LLC | 19 mi |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | 19 mi |
| A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies | Phase 1 | SEED Therapeutics, Inc. | 19 mi |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | Crinetics Pharmaceuticals Inc. | 19 mi |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | Phase 2 | Alzheimer's Disease Cooperative Study (ADCS) | 19 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 19 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Phase 3 | Eli Lilly and Company | 19 mi |
| EDX110 Randomized Control Trial for Treatment of DFUs | N/A | ConvaTec Inc. | 19 mi |
| Conscious Pregnancy: Supporting Maternal Cardiometabolic Health With Mindfulness | N/A | University of California, Irvine | 19 mi |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | 19 mi |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | 19 mi |
| Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease | Phase 1/2 | NKGen Biotech, Inc. | 19 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | 20 mi |
| Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | 20 mi |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | Phase 3 | AbbVie | 20 mi |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | Phase 2 | NRG Oncology | 20 mi |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | 20 mi |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | Phase 1/2 | Regeneron Pharmaceuticals | 20 mi |
| Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 20 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | 20 mi |
| Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With Gastric Cancer Spread to the Abdominal Cavity | Phase 2/3 | ECOG-ACRIN Cancer Research Group | 20 mi |
| Iberdomide Versus Observation Off Therapy After Idecabtagene Vicleucel CAR-T for Multiple Myeloma | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | 20 mi |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | Phase 3 | Alliance for Clinical Trials in Oncology | 20 mi |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | Alliance for Clinical Trials in Oncology | 20 mi |
| CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | Phase 1/2 | National Cancer Institute (NCI) | 20 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | 20 mi |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer | Phase 3 | NRG Oncology | 20 mi |
| Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial | Phase 2 | Alliance for Clinical Trials in Oncology | 20 mi |
| An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms | Phase 1/2 | University of California, Irvine | 20 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | 20 mi |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer | Phase 1/2 | National Cancer Institute (NCI) | 20 mi |
| Neoadjuvant Chemotherapy, Excision And Observation vs Chemoradiotherapy For Rectal Cancer | Phase 3 | Canadian Cancer Trials Group | 20 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | 20 mi |
| Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics | 20 mi |
| Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | 20 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | 20 mi |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Phase 2/3 | Bristol-Myers Squibb | 20 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | 20 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | 20 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC) | Phase 1 | AbbVie | 20 mi |
| A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 20 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | 20 mi |
| Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial | Phase 1/2 | National Cancer Institute (NCI) | 20 mi |
| Durvalumab With Gemcitabine and Cisplatin for the Treatment of High-Risk Resectable Liver Cancer Before Surgery | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial | Phase 3 | NRG Oncology | 20 mi |
| A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) | Phase 2/3 | AbbVie | 20 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | 20 mi |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Phase 2 | Eli Lilly and Company | 20 mi |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Phase 1/2 | Cabaletta Bio | 20 mi |
| Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma | Phase 1 | Sorrento Therapeutics, Inc. | 20 mi |
| Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial | N/A | University of California, Irvine | 20 mi |
| Exparel vs. ACB With Bupivacaine for ACL Reconstruction | Phase 1 | Children's Hospital of Orange County | 20 mi |
| Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination | Phase 1/2 | Merus B.V. | 20 mi |
| Single-Center Eval of Clinical & Radiological Benefit AHCC in Combo W/ SOC Tx for HPV+ Pts W/ HNSCC | Phase 2 | University of California, Irvine | 20 mi |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Phase 3 | UroGen Pharma Ltd. | 20 mi |
| realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL | — | Incyte Corporation | 20 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | 20 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | 20 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | 20 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | 20 mi |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (RemeMG) | Phase 3 | Vor Biopharma | 20 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 20 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | 20 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | 20 mi |
| Groningen International Study on Sentinel Nodes in Vulvar Cancer-III | Phase 2 | University Medical Center Groningen | 20 mi |
| Efficacy and Safety of the CG-100 Intraluminal Bypass Device | N/A | Colospan Ltd. | 20 mi |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 20 mi |
| mpMRI Compared to Diagnostic TURBT in Patients With Suspected Muscle-Invasive Bladder Cancer | N/A | University of California, Irvine | 20 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | 20 mi |
| Study of SGN1 in Patients With Advanced Solid Tumor | Phase 1/2 | Guangzhou Sinogen Pharmaceutical Co., Ltd | 20 mi |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Phase 1/2 | Tanja Andrea Gruber | 20 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | 20 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | 20 mi |
| PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis | Early 1 | University of California, Irvine | 20 mi |
| Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies | Phase 1 | AbbVie | 20 mi |
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Phase 2 | BioNTech SE | 20 mi |
| A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1) | Phase 1/2 | Janssen Research & Development, LLC | 20 mi |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | 20 mi |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | 20 mi |
| A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy | Phase 1 | Children's Oncology Group | 20 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | 20 mi |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Phase 1 | Carna Biosciences, Inc. | 20 mi |
| Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL | Phase 2 | Etan Orgel | 20 mi |
| AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Phase 2 | AstraZeneca | 20 mi |
| The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | Phase 3 | Telix Pharmaceuticals (Innovations) Pty Limited | 20 mi |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | 20 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | 20 mi |
| DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Delta-Fly Pharma, Inc. | 20 mi |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | Phase 2 | AstraZeneca | 20 mi |
| Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma | Phase 1 | Children's Oncology Group | 20 mi |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | Phase 1/2 | Perspective Therapeutics | 20 mi |
| Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation | Phase 2 | University of California, Irvine | 20 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | 20 mi |
| rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | Phase 1 | Ann & Robert H Lurie Children's Hospital of Chicago | 20 mi |
| A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC | Phase 2/3 | Urovant Sciences GmbH | 20 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | 20 mi |
| Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Kura Oncology, Inc. | 20 mi |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | Phase 2/3 | Taiho Oncology, Inc. | 20 mi |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | 20 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Use of Levocarnitine to Reduce Asparaginase Hepatotoxicity in Patients With Acute Lymphoblastic Leukemia | Early 1 | Children's Hospital of Orange County | 20 mi |
| Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | Phase 1/2 | SWOG Cancer Research Network | 20 mi |
| Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study | Phase 2 | Vanderbilt-Ingram Cancer Center | 20 mi |
| Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis | N/A | University of California, Irvine | 20 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | 20 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | 20 mi |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Phase 1/2 | D3 Bio (Wuxi) Co., Ltd | 20 mi |
| Study to Assess Safety, Efficacy, and Cellular Kinetics of YTB323 in Generalized Myasthenia Gravis | Phase 1/2 | Novartis Pharmaceuticals | 20 mi |
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Phase 2/3 | Kyverna Therapeutics | 20 mi |
| A Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer | Phase 3 | J-Pharma Co., Ltd. | 20 mi |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Phase 3 | AstraZeneca | 20 mi |
| Study of TJ033721 (givastomig) in Subjects with Advanced or Metastatic Solid Tumors | Phase 1 | I-Mab Biopharma US Limited | 20 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 20 mi |
| Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | Phase 1 | University of California, Irvine | 20 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | 20 mi |
| A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | Phase 1 | PureTech | 20 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | 20 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | 20 mi |
| Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma | Early 1 | New York Medical College | 20 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | 20 mi |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Phase 1/2 | Terns, Inc. | 20 mi |
| A Study of Narmafotinib Given in Combination With Modified FOLFIRINOX in Patients With Metastatic Pancreatic Cancer | Phase 1/2 | Amplia Therapeutics Limited | 20 mi |
| A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma | Phase 3 | Takeda | 20 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | 20 mi |
| A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | Phase 2 | Pierre Fabre Medicament | 20 mi |
| Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | Phase 1/2 | Washington University School of Medicine | 20 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | 20 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 20 mi |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) | Phase 1 | University of California, Irvine | 20 mi |
| Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | Phase 2 | University of California, Irvine | 20 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | 20 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | 20 mi |
| Testing the Addition of an Anti-cancer Drug, DT2216, to the Usual Chemotherapy Treatment for Relapsed or Refractory Solid Tumors and Fibrolamellar Carcinoma | Phase 1/2 | Children's Oncology Group | 20 mi |
| A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | 20 mi |
| A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment | Phase 1/2 | Regeneron Pharmaceuticals | 20 mi |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | Phase 1/2 | National Cancer Institute (NCI) | 20 mi |
| Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts W/Chronic Myeloid Leukemia | — | University of California, Irvine | 20 mi |
| Study of ONO-4685 in Patients With Relapsed or Refractory T Cell Lymphoma | Phase 1 | Ono Pharmaceutical Co. Ltd | 20 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | 20 mi |
| A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) | Phase 3 | BeiGene | 20 mi |
| Childhood Cancer Survivor Study | — | St. Jude Children's Research Hospital | 20 mi |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Phase 3 | Day One Biopharmaceuticals, Inc. | 20 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | 20 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | 20 mi |
| Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Phase 1/2 | Lantheus Medical Imaging | 20 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | 20 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | 20 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | 20 mi |
| Vitaccess Real MG Registry | — | Vitaccess Ltd | 20 mi |
| A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | 20 mi |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Phase 1 | Caribou Biosciences, Inc. | 20 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | 20 mi |
| Adjuvant Sacituzumab Govitecan and Nivolumab in Muscle-Invasive Urothelial Carcinoma At High-Risk Recurrence | Phase 2 | University of California, Irvine | 20 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | 20 mi |
| TrialNet Pathway to Prevention of T1D | — | University of South Florida | 20 mi |
| Trial-Ready Cohort-Down Syndrome (TRC-DS) | — | University of Southern California | 20 mi |
| Evaluating Novel Healthcare Approaches to Nurturing and Caring for Hospitalized Elders | N/A | University of Michigan | 20 mi |
| An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | Phase 2 | Zomagen Biosciences Ltd. | 20 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | 20 mi |
| AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor | — | Peerbridge Health, Inc | 20 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | 20 mi |
| AngelMed Guardian® System PMA Post Approval Study | — | Angel Medical Systems | 20 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | 20 mi |
| Cord Clamping Among Neonates With Congenital Heart Disease | N/A | Carl Backes, MD | 20 mi |
| Optimal Ventilation for Cardiac Arrest | N/A | Children's Hospital of Philadelphia | 20 mi |
| Cardiac Structure and Function in MPS | — | Children's Hospital of Orange County | 20 mi |
| A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | 20 mi |
| ATrial Tachycardia PAcing Therapy in Congenital Heart | — | Ian Law | 20 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | 20 mi |
| TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age | — | State University of New York at Buffalo | 20 mi |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | 20 mi |
| VIBRANT: VIB4920 for Active Lupus Nephritis | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | 20 mi |
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | Phase 1/2 | Cabaletta Bio | 20 mi |
| A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease | — | TScan Therapeutics, Inc. | 20 mi |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Phase 3 | TG Therapeutics, Inc. | 20 mi |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | 20 mi |
| A Study of XMT-1660 in Participants With Solid Tumors | Phase 1 | Mersana Therapeutics | 20 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies | Phase 1/2 | University of California, Irvine | 20 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 20 mi |
| ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | Persephone Biosciences | 20 mi |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase 3 | Nuvalent Inc. | 20 mi |
| Assess Diversity of Gut Microbiome in Met NSCLC in Correlation to Tx & Adverse Effects | — | University of California, Irvine | 20 mi |
| Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | — | Lung Cancer Mutation Consortium | 20 mi |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | Phase 1/2 | Frontier Medicines Corporation | 20 mi |
| Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders | Phase 2 | Carl Allen | 20 mi |
| AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | Phase 1 | Amgen | 20 mi |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | Phase 2 | Eikon Therapeutics | 20 mi |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Phase 2 | Janssen Research & Development, LLC | 20 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | 20 mi |
| Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer | N/A | University of California, Irvine | 20 mi |
| Study of RET Inhibitor TAS0953/HM06 in Patients with Advanced Solid Tumors with RET Gene Abnormalities | Phase 1/2 | Taiho Pharmaceutical Co., Ltd. | 20 mi |
| A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC | Phase 1/2 | AstraZeneca | 20 mi |
| A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | Phase 1 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 20 mi |
| A Long-term Extension Study of PCI-32765 (Ibrutinib) | Phase 3 | Janssen Research & Development, LLC | 20 mi |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Eli Lilly and Company | 20 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | 20 mi |
| A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC | Phase 1/2 | J Ints Bio | 20 mi |
| A Study of VET3-TGI in Patients With Solid Tumors | Phase 1 | KaliVir Immunotherapeutics | 20 mi |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Revolution Medicines, Inc. | 20 mi |
| A Study of DF6002 Alone and in Combination With Nivolumab | Phase 1 | Dragonfly Therapeutics | 20 mi |
| First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors | Phase 1 | Plexium, Inc. | 20 mi |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | Phase 1 | TopAlliance Biosciences | 20 mi |
| A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Regeneron Pharmaceuticals | 20 mi |
| Study of DF6215 in Patients with Advanced Solid Tumors | Phase 1 | Dragonfly Therapeutics | 20 mi |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Deciphera Pharmaceuticals, LLC | 20 mi |
| The Myelin Disorders Biorepository Project | — | Children's Hospital of Philadelphia | 20 mi |
| Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | N/A | ABK Biomedical | 20 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | 20 mi |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | Phase 1/2 | Children's Oncology Group | 20 mi |
| Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers | N/A | University of California, Irvine | 20 mi |
| Combination of TATE and PD-1 Inhibitor in Liver Cancer | Phase 2 | Teclison Ltd. | 20 mi |
| Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial | Phase 2 | University of California, Irvine | 20 mi |
| Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma | Phase 2 | University of California, Irvine | 20 mi |
| TATE and Pembrolizumab (MK3475) in mCRC and NSCLC | Phase 2 | Teclison Ltd. | 20 mi |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | — | Boston Scientific Corporation | 20 mi |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Krystal Biotech, Inc. | 20 mi |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Aptose Biosciences Inc. | 20 mi |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | Phase 1/2 | VBI Vaccines Inc. | 20 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | 20 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | 20 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | 20 mi |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | Phase 2 | City of Hope Medical Center | 20 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | 20 mi |
| Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma. | Phase 1 | BioAtla, Inc. | 20 mi |
| Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | 20 mi |
| Study of LYL314 in Aggressive Large B-Cell Lymphoma | Phase 1/2 | Lyell Immunopharma, Inc. | 20 mi |
| Tarlatamab in Advanced Delta-like 3 (DLL3)-Expressing Tumors Including Neuroendocrine Neoplasms | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study | Phase 3 | Steba Biotech S.A. | 20 mi |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Phase 1/2 | Astellas Pharma Global Development, Inc. | 20 mi |
| Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma | Phase 3 | Alliance for Clinical Trials in Oncology | 20 mi |
| A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | 20 mi |
| A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 20 mi |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | 20 mi |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Fusion Pharmaceuticals Inc. | 20 mi |
| GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | 20 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | 20 mi |
| ALT-FLOW II Trial of the Edwards APTURE Transcatheter Shunt System | N/A | Edwards Lifesciences | 20 mi |
| Innovations in Genicular Outcomes Registry | — | Pacira Pharmaceuticals, Inc | 20 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | 20 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | 20 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | 20 mi |
| Women Informed to Screen Depending on Measures of Risk (Wisdom Study) | N/A | University of California, San Francisco | 20 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | 20 mi |
| Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Phase 1/2 | Phoenix Molecular Designs | 20 mi |
| A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | Phase 3 | Hoffmann-La Roche | 20 mi |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | 20 mi |
| Study of DF1001 in Patients with Advanced Solid Tumors | Phase 1/2 | Dragonfly Therapeutics | 20 mi |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | 20 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | 20 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | 20 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Immunovant Sciences GmbH | 20 mi |
| A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 3 | Janssen Research & Development, LLC | 20 mi |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) | Phase 2 | Alto Neuroscience | 20 mi |
| Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Prevention of Frailty With Fisetin and Exercise in Breast Cancer Survivors | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer | Phase 1 | Boehringer Ingelheim | 20 mi |
| Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy | Phase 2 | BioNTech SE | 20 mi |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Phase 1/2 | Eisai Inc. | 20 mi |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Phase 3 | Advenchen Laboratories, LLC | 20 mi |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Servier Bio-Innovation LLC | 20 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | 20 mi |
| This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors | Phase 1 | ABL Bio, Inc. | 20 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | 20 mi |
| Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas | Phase 1 | Inhibrx Biosciences, Inc | 20 mi |
| Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | Phase 1 | Oxford BioTherapeutics Ltd | 20 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | 20 mi |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Phase 3 | Kite, A Gilead Company | 20 mi |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Phase 2/3 | Inhibrx Biosciences, Inc | 20 mi |
| Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | Phase 1/2 | Neonc Technologies, Inc. | 20 mi |
| A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer | Phase 1 | Aura Biosciences | 20 mi |
| NEO100 and High-Grade Meningioma | Phase 2 | Neonc Technologies, Inc. | 20 mi |
| A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment | Phase 2 | Cedars-Sinai Medical Center | 20 mi |
| A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion (MTAPESTRY 103) | Phase 1 | Amgen | 20 mi |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/3 | Biogen | 20 mi |
| Relationship Between Data Obtained With the LuGENE® Multiparameter Transcriptomics Blood Test and Clinical and Standard Laboratory Features of Patients With SLE (ReLATE) | — | Ampel BioSolutions, LLC | 20 mi |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | 20 mi |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | Phase 3 | Bristol-Myers Squibb | 20 mi |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | Phase 1 | Pfizer | 20 mi |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Amgen | 20 mi |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 20 mi |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | 20 mi |
| ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 20 mi |
| ADSTILADRIN Early Utilization and Outcomes in the Real World Setting | — | Ferring Pharmaceuticals | 20 mi |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/3 | IDEAYA Biosciences | 20 mi |
| PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2 | N/A | Weill Medical College of Cornell University | 20 mi |
| A Pediatric and Young Adult Trial of Genetically Modified T Cells Directed Against CD22 for Relapsed/Refractory Leukemia or Lymphoma | Phase 1/2 | Seattle Children's Hospital | 20 mi |
| Evaluation of Pharmacokinetics, Pharmacodynamics, Efficacy, Safety, and Immunogenicity of Ravulizumab Administered Intravenously in Pediatric Participants With Generalized Myasthenia Gravis (gMG) | Phase 3 | Alexion Pharmaceuticals, Inc. | 20 mi |
| SPECT/CT for the Characterization of Renal Masses | — | Jonsson Comprehensive Cancer Center | 20 mi |
| A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | — | Bayer | 20 mi |
| A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's | N/A | Compedica Inc | 20 mi |
| A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance | Phase 4 | AbbVie | 20 mi |
| Terazosin and Parkinson's Disease Extension Study | Phase 2 | Cedars-Sinai Medical Center | 20 mi |
| Terazosin Effect on Cardiac Changes in Early Parkinson's Disease | Phase 2 | Cedars-Sinai Medical Center | 20 mi |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | Phase 1 | Atavistik Bio, Inc | 20 mi |
| A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | Phase 1/2 | Ascendis Pharma Oncology Division A/S | 20 mi |
| Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study) | — | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 20 mi |
| Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors | Phase 1/2 | Qurient Co., Ltd. | 20 mi |
| Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma | N/A | University of California, San Francisco | 20 mi |
| Neurocognition in Congenital Central Hypoventilation Syndrome (CCHS) | — | Debra Weese-Mayer | 20 mi |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | — | Tufts Medical Center | 20 mi |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Phase 2 | OncoVerity, Inc. | 20 mi |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | Phase 3 | Novartis Pharmaceuticals | 20 mi |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1 | Cullinan Therapeutics Inc. | 20 mi |
| Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | 20 mi |
| Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | Phase 2 | University of Southern California | 20 mi |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | Phase 1/2 | Merck Sharp & Dohme LLC | 20 mi |
| Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Phase 1/2 | Deciphera Pharmaceuticals, LLC | 20 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | 20 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | 20 mi |
| Combination Therapy for the Treatment of Diffuse Midline Gliomas | Phase 2 | University of California, San Francisco | 20 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 20 mi |
| [Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application | Phase 1/2 | FutureChem | 20 mi |
| Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors | N/A | University of Southern California | 20 mi |
| Using Augmented Reality to Promote Physical Activity in Children With Cerebral Palsy | N/A | Children's Hospital Los Angeles | 20 mi |
| Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021) | Phase 1 | University of California, San Francisco | 20 mi |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | BioNTech SE | 20 mi |
| A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors | Phase 1/2 | BioInvent International AB | 20 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | 20 mi |
| Association Between Exercise, Patient-Reported Outcomes, and Clinical Events in Adult Cancer Survivors | — | Memorial Sloan Kettering Cancer Center | 20 mi |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Janssen Research & Development, LLC | 20 mi |
| TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) | — | University of Colorado, Denver | 20 mi |
| Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Phase 2 | AstraZeneca | 20 mi |
| A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours) | Phase 1 | Boehringer Ingelheim | 20 mi |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Phase 2 | Cogent Biosciences, Inc. | 20 mi |
| FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Fulgent Pharma LLC. | 20 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | 20 mi |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | Phase 2 | Stemline Therapeutics, Inc. | 20 mi |
| Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma | Phase 2/3 | TuHURA Biosciences, Inc. | 20 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | Phase 1/2 | Nimbus Wadjet, Inc. | 20 mi |
| Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Active Surveillance for Cancer of the Prostate (ASCaP) | — | Jonsson Comprehensive Cancer Center | 20 mi |
| REMASTer: REcurrent Brain Metastases After SRS Trial | N/A | Monteris Medical | 20 mi |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | Phase 2/3 | Janssen Research & Development, LLC | 20 mi |
| Interstitial Brachytherapy for the Treatment of Unresectable/Unablatable Kidney Cancer | Phase 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging. | Phase 3 | University of Alberta | 20 mi |
| REtroperitoneal SArcoma Registry: an International Prospective Initiative | — | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | 20 mi |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Phase 1 | Poseida Therapeutics, Inc. | 20 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) | Phase 1/2 | AbbVie | 20 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | 20 mi |
| A Study of Lorigerlimab in Participants With Advanced Solid Tumors | Phase 2 | MacroGenics | 20 mi |
| A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 3 | Genmab | 20 mi |
| Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC) | — | Tempus AI | 20 mi |
| 18F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer | Phase 4 | VA Greater Los Angeles Healthcare System | 20 mi |
| A Study for Participants Previously Treated With Century Therapeutics Cellular Therapy Product | — | Century Therapeutics, Inc. | 20 mi |
| Image-Guided Biopsies to Identify Mechanisms of Resistance in Patients With Metastatic Castration Resistant Prostate Cancer Treated With 177Lu-PSMA Radioligand Therapy | Phase 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer | Phase 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| 99mTc-PSMA-I&S Biodistribution in Patients With Prostate Cancer | Early 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial | Phase 2 | New Approaches to Neuroblastoma Therapy Consortium | 20 mi |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase 2 | IDEAYA Biosciences | 20 mi |
| Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | Phase 1/2 | Genfit | 20 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | 20 mi |
| Predicting BCG Response | — | Cedars-Sinai Medical Center | 20 mi |
| Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy | — | National Cancer Institute (NCI) | 20 mi |
| A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | Phase 2 | Ono Pharmaceutical Co. Ltd | 20 mi |
| An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Teva Branded Pharmaceutical Products R&D, Inc. | 20 mi |
| Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients | Phase 1/2 | Charles Drew University of Medicine and Science | 20 mi |
| Study of FID-022 in Participants With Advanced Solid Tumors | Phase 1 | Fulgent Pharma LLC. | 20 mi |
| Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer | Phase 2 | Cedars-Sinai Medical Center | 20 mi |
| Comparing a New PSMA Imaging Agent to MRI for Detecting Prostate Cancer, BEACON Trial | Early 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 2 | Orca Biosystems, Inc. | 20 mi |
| (HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis | Phase 2/3 | Blueprint Medicines Corporation | 20 mi |
| Pembrolizumab and Enfortumab Vedotin With Pembrolizumab Prior to and After Radical Nephroureterectomy for High-Risk Upper Tract Urothelial Cancer | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase 1 | Cullinan Therapeutics Inc. | 20 mi |
| WATER IV Prostate Cancer | N/A | PROCEPT BioRobotics | 20 mi |
| Actinium Therapy for Late-stage Aggressive Sarcomas | Phase 1 | Ratio Therapeutics, Inc. | 20 mi |
| Feasibility of Remote Activity Assessment and PRO Collection Among Transgender Cancer Survivors | — | Cedars-Sinai Medical Center | 20 mi |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Phase 1/2 | Merus B.V. | 20 mi |
| ZZ06 in Adult Patients With Advanced Solid Tumor Malignancies | Phase 1 | Changchun Intellicrown Pharmaceutical Co. LTD | 20 mi |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | 20 mi |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions | Phase 1/2 | IDEAYA Biosciences | 20 mi |
| A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | 20 mi |
| CoGENES Randomized Controlled Trial (RCT) | N/A | University of Southern California | 20 mi |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | 20 mi |
| Relacorilant With Nab-Paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Adenocarcinoma | Phase 2 | Corcept Therapeutics | 20 mi |
| CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children | Phase 1 | City of Hope Medical Center | 20 mi |
| PH Sensitive MRI Based Resections of Glioblastoma | Phase 1 | University of California, Los Angeles | 20 mi |
| A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors | Phase 1 | Sapience Therapeutics | 20 mi |
| High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma | Phase 1/2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Community Partnership for Telehealth Solutions to Counter Misinformation and Achieve Equity | N/A | University of Arizona | 20 mi |
| Phase II Study of 5-Day Hypofractionated Preoperative Radiation Therapy for Soft Tissue Sarcomas: Expansion Cohort | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | 20 mi |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) | Phase 1/2 | Cellectis S.A. | 20 mi |
| Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | Phase 1/2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure | Phase 2 | Brian Jonas | 20 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | 20 mi |
| Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| RB Liquid Biopsy Biorepository | — | Children's Hospital Los Angeles | 20 mi |
| Image-Guidance and Online Adaptation With Stereotactic Body Radiation Therapy for the Treatment of Localized Prostate Cancer, MANTICORE Trial | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Phase 1/2 | Indapta Therapeutics, INC. | 20 mi |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Phase 3 | Iovance Biotherapeutics, Inc. | 20 mi |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Phase 1 | AbbVie | 20 mi |
| Blue Light Cystoscopy With Cysview® Registry | — | Photocure | 20 mi |
| A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) | Phase 1/2 | Merck Sharp & Dohme LLC | 20 mi |
| International Rare Brain Tumor Registry | — | Children's National Research Institute | 20 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | 20 mi |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | Phase 3 | Regeneron Pharmaceuticals | 20 mi |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 20 mi |
| A Study of PHST001 in Advanced Solid Tumors | Phase 1 | Pheast Therapeutics | 20 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | 20 mi |
| Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | 20 mi |
| Pea Protein Oral Nutrition Supplement for the Reduction of Gastrostomy Tube Placement Rate in Patients With Locally Advanced Head and Neck Cancer Undergoing Chemoradiation Therapy | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Selinexor and Backbone Treatments of Multiple Myeloma Patients | Phase 1/2 | Karyopharm Therapeutics Inc | 20 mi |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Phase 3 | PharmaMar | 20 mi |
| Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells | Phase 1/2 | Jonsson Comprehensive Cancer Center | 20 mi |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase 1/2 | Corbus Pharmaceuticals Inc. | 20 mi |
| Study of Canakinumab in Patients With Myelofibrosis | Phase 2 | John Mascarenhas | 20 mi |
| Testing eSCCIP: An eHealth Psychosocial Intervention for English and Spanish Speaking Parents of Children With Cancer | N/A | Nemours Children's Clinic | 20 mi |
| Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | Phase 2 | Fred Hutchinson Cancer Center | 20 mi |
| Primary Tumor Research and Outcomes Network | — | AO Innovation Translation Center | 20 mi |
| Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | Phase 1/2 | Chirag G. Patil | 20 mi |
| Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | Phase 1 | SciTech Development, Inc. | 20 mi |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Phase 1/2 | Replimune Inc. | 20 mi |
| Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study | N/A | University of California, Los Angeles | 20 mi |
| Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations | — | Boston Children's Hospital | 20 mi |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Kura Oncology, Inc. | 20 mi |
| Fluoxetine for the Modification of Colorectal Tumor Immune Cells Before Surgery in Patients With Colorectal Cancer | Phase 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| Pituitary Tumor Surveillance: Pathogenic Correlation | — | Cedars-Sinai Medical Center | 20 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | 20 mi |
| Vascular Optimized Radiotherapy Tuned to Critical Structures for Erectile Function Using High-Precision X-Ray Treatment | Phase 3 | Jonsson Comprehensive Cancer Center | 20 mi |
| Lurbinectedin in FET-Fused Tumors | Phase 1/2 | Children's Hospital of Philadelphia | 20 mi |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 20 mi |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | 20 mi |
| Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms | — | University of California, San Francisco | 20 mi |
| Active Surveillance of Papillary Thyroid Microcarcinoma | N/A | Cedars-Sinai Medical Center | 20 mi |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Phase 1/2 | Regeneron Pharmaceuticals | 20 mi |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors | Phase 1 | Debiopharm International SA | 20 mi |
| Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy | N/A | Cedars-Sinai Medical Center | 20 mi |
| Proactive Costs of Care Study | N/A | Cedars-Sinai Medical Center | 20 mi |
| Micro-UltraSound In Cancer - Active Surveillance | N/A | University of Alberta | 20 mi |
| Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus | N/A | Northwestern University | 20 mi |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 2 | Incyte Corporation | 20 mi |
| Ivonescimab for the Treatment of Thymic Cancer | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Phase 1/2 | Daiichi Sankyo | 20 mi |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Phase 1/2 | University of California, San Francisco | 20 mi |
| Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant | Phase 1 | Ronald Paquette | 20 mi |
| LIFE Cancer Survivorship Database for Pediatric Cancer | — | Children's Hospital Los Angeles | 20 mi |
| A Platform Study of Epigenetic Therapy Before Prostatectomy in Men With Prostate Cancer | Early 1 | Edwin Posadas, MD | 20 mi |
| CATALINA-4: A Study to Investigate the Safety and Efficacy of TORL-1-23 With Chemotherapy Given Before Initial Surgery in Women With Advanced Stage Ovarian Cancer | Phase 1/2 | TORL Biotherapeutics, LLC | 20 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology | Phase 2 | Leslie Ballas | 20 mi |
| A Study of EP0031 in Patients With Advanced RET-altered Malignancies | Phase 1/2 | Ellipses Pharma | 20 mi |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | Phase 1 | Pfizer | 20 mi |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Kyntra Bio | 20 mi |
| Integrating Quantitative MRI and Artificial Intelligence to Improve Prostate Cancer Classification | — | Jonsson Comprehensive Cancer Center | 20 mi |
| Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1 | Phase 2 | University of Alabama at Birmingham | 20 mi |
| Role of Race in Nutritional Approach in Men on ADT | N/A | University of California, Los Angeles | 20 mi |
| Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal) | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | Phase 3 | St. Louis University | 20 mi |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Phase 1/2 | Janssen Research & Development, LLC | 20 mi |
| Advanced Magnetic Resonance Imaging for the Identification of Recurrent Brain Tumors and Radiation Necrosis | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment | Phase 1 | Memorial Sloan Kettering Cancer Center | 20 mi |
| Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | Phase 1/2 | Lantheus Medical Imaging | 20 mi |
| At-Home Cardiac Rehabilitation for Adolescents at Risk for Heart Failure | N/A | Children's Hospital Los Angeles | 20 mi |
| Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease | Phase 2 | University of California, Los Angeles | 20 mi |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 20 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | 20 mi |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Phase 3 | Celgene | 20 mi |
| Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study | — | M.D. Anderson Cancer Center | 20 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | 20 mi |
| A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma | Phase 2 | Sarcoma Alliance for Research through Collaboration | 20 mi |
| NLP-Based Feedback to Improve Risk Comms and Informed Shared Decision Making | N/A | Cedars-Sinai Medical Center | 20 mi |
| A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML) | Phase 1 | Bio-Path Holdings, Inc. | 20 mi |
| Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) | Phase 2 | AstraZeneca | 20 mi |
| Yttrium-90 (Y90) Radioembolization for the Treatment of Early Stage Renal Cell Carcinoma, The RENEGADE Trial | Phase 1/2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Phase 1 | SystImmune Inc. | 20 mi |
| Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | Phase 3 | GlaxoSmithKline | 20 mi |
| Improving Colonoscopy Surveillance for Patients With High Risk Colon Polyps | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| A First-in-Human (FIH) Study of BG-C137, an Anti-Fibroblast Growth Factor Receptor 2b (FGFR2b) Antibody Drug Conjugate, in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 20 mi |
| A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 20 mi |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Phase 1 | National Cancer Institute (NCI) | 20 mi |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | Phase 2 | Alliance for Clinical Trials in Oncology | 20 mi |
| Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors | Phase 2 | AstraZeneca | 20 mi |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Prescription of Letrozole for Uterine Myoma | Phase 4 | University of California, San Francisco | 20 mi |
| Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination with XELOX or Irinotecan in Patients with Advanced Gastric Cancer | Phase 1/2 | Idience Co., Ltd. | 20 mi |
| Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity | — | Jonsson Comprehensive Cancer Center | 20 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | 20 mi |
| Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 3 | Incyte Corporation | 20 mi |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Myriad™ Augmented Soft Tissue Reconstruction Registry | — | Aroa Biosurgery Limited | 20 mi |
| EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection | Phase 2 | New York Medical College | 20 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | 20 mi |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | Phase 2 | Iovance Biotherapeutics, Inc. | 20 mi |
| Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD | N/A | Dana-Farber Cancer Institute | 20 mi |
| A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia | Phase 1/2 | Therapeutic Advances in Childhood Leukemia Consortium | 20 mi |
| Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | Phase 2 | Edwin Posadas, MD | 20 mi |
| Post-Exablate Pregnancy Outcomes Registry Study: Exablate Treatment of Symptomatic Uterine Fibroids | — | InSightec | 20 mi |
| HIFU for Focal Ablation of Prostate Tissue: An Observational Study | — | University of California, Los Angeles | 20 mi |
| Characterization of T-cell Repertoire in Patients With Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant | — | University of Southern California | 20 mi |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | Phase 2 | NYU Langone Health | 20 mi |
| Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma | Phase 1/2 | National Cancer Institute (NCI) | 20 mi |
| Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors | Phase 1/2 | Shionogi | 20 mi |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Phase 1/2 | Immunocore Ltd | 20 mi |
| A Study of LM-24C5 For Advanced Solid Tumors | Phase 1/2 | LaNova Medicines Limited | 20 mi |
| Norris ORIEN Total Cancer Care | — | University of Southern California | 20 mi |
| Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr | N/A | Weill Medical College of Cornell University | 20 mi |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | Cybrexa Therapeutics | 20 mi |
| Pembrolizumab in Treating Participants With Leukoplakia | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Phase 1/2 | Georgiamune Inc | 20 mi |
| A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu... | N/A | National Cancer Institute (NCI) | 20 mi |
| Neuroblastoma Biology Study | — | New Approaches to Neuroblastoma Therapy Consortium | 20 mi |
| Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula | Phase 3 | SWOG Cancer Research Network | 20 mi |
| Mechanisms of Resistance to PSMA Radioligand Therapy | — | University of California, San Francisco | 20 mi |
| International REgistry of COnservative or Radical Treatment of Localized Kidney Tumors | — | Azienda Ospedaliero-Universitaria Careggi | 20 mi |
| Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence | N/A | Nicole Baca | 20 mi |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | Phase 2/3 | Eikon Therapeutics | 20 mi |
| Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06) | Phase 1/2 | Merck Sharp & Dohme LLC | 20 mi |
| Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor | Phase 2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 20 mi |
| Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma | Phase 2 | Joseph Tuscano | 20 mi |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | 20 mi |
| Impact of Protect Your Colon™ on CRC Screening | N/A | Cedars-Sinai Medical Center | 20 mi |
| A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body | Phase 1/2 | Regeneron Pharmaceuticals | 20 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | 20 mi |
| An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Liquid Biopsies in Pediatric Solid Tumors | — | Children's Hospital Los Angeles | 20 mi |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | 20 mi |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 2 | Gilead Sciences | 20 mi |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Phase 1/2 | Vironexis Biotherapeutics Inc. | 20 mi |
| High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | 20 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | 20 mi |
| Trial of DFP-14927 in Advanced Solid Tumors | Phase 1 | Delta-Fly Pharma, Inc. | 20 mi |
| Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) | Phase 1/2 | Merck Sharp & Dohme LLC | 20 mi |
| A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma | Phase 3 | Regeneron Pharmaceuticals | 20 mi |
| Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies | Phase 1 | Joshua Sasine, MD, PhD | 20 mi |
| Bright Ideas - CIN Feasibility Study | N/A | The Hospital for Sick Children | 20 mi |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Phase 1/2 | Merck Sharp & Dohme LLC | 20 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | 20 mi |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | Phase 1/2 | BeOne Medicines | 20 mi |
| Development of Liquid Biopsy Technologies for Noninvasive Cancer Diagnostics in Patients With Suspicious Thyroid Nodules or Thyroid Cancer | — | Jonsson Comprehensive Cancer Center | 20 mi |
| Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | 20 mi |
| Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) | Phase 1/2 | Phanes Therapeutics | 20 mi |
| A Clinic-wide Intervention (Primary Care-GI Connect) for Improving Rates of Colonoscopy After Abnormal Fecal Immunochemical Test Result in Patients at Federally Qualified Health Centers | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | Phase 2 | Disc Medicine, Inc | 20 mi |
| A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study | Phase 1 | Novartis Pharmaceuticals | 20 mi |
| Computed Tomography-Guided Stereotactic Body Radiation Therapy With Intrafraction Motion Monitoring for the Treatment of Localized Prostate Cancer, ILLUSION Trial | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas | — | University of Michigan Rogel Cancer Center | 20 mi |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Phase 3 | Clarity Pharmaceuticals Ltd | 20 mi |
| MRI-Based Machine Learning Approach Versus Radiologist MRI Reading for the Detection of Prostate Cancer, The PRIMER Trial | N/A | University of Southern California | 20 mi |
| eMOTION: Examining Implicit Attitudes in Physical Activity Engagement | — | University of Southern California | 20 mi |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | 20 mi |
| Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (FLEX-MRT) | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | N/A | Alpha Tau Medical LTD. | 20 mi |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma | Phase 2 | National Cancer Institute (NCI) | 20 mi |
| Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma | Phase 2 | Jazz Pharmaceuticals | 20 mi |
| Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | Phase 1/2 | Cantex Pharmaceuticals | 20 mi |
| Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis | Phase 1/2 | Nexcella Inc. | 20 mi |
| Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer | — | Jonsson Comprehensive Cancer Center | 20 mi |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Phase 2 | Regeneron Pharmaceuticals | 20 mi |
| Confronting Cancer as a Community | N/A | University of Southern California | 20 mi |
| A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Phase 1 | BlossomHill Therapeutics | 20 mi |
| Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults | Phase 1 | Sabine Mueller, MD, PhD | 20 mi |
| Personalized Health Self-Management Training for Colorectal Cancer Survivors | N/A | University of Southern California | 20 mi |
| A Study to Give Treatment Inside the Eye to Treat Retinoblastoma | Phase 2 | Children's Oncology Group | 20 mi |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | Phase 3 | Institute of Cancer Research, United Kingdom | 20 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | 20 mi |
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | Phase 2 | Wugen, Inc. | 20 mi |
| Topical Imiquimod Treatment of Oral Dysplasia | Phase 1/2 | University of Southern California | 20 mi |
| Intraoperative Imaging of Gastrointestinal Malignancies Using Pafolacianine (CYTALUX™) | Phase 4 | Cedars-Sinai Medical Center | 20 mi |
| Hypofractionated External Beam Radiotherapy With Adaptive Planning for Endometrial and Cervical Cancers | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma | Phase 3 | Arcus Biosciences, Inc. | 20 mi |
| ColoCare Study - Colorectal Cancer Cohort | — | University of Utah | 20 mi |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | Boehringer Ingelheim | 20 mi |
| A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma | — | Aura Biosciences | 20 mi |
| RCT of NLP-Based Feedback for Improving SDM in Men With Localized Prostate Cancer | N/A | Cedars-Sinai Medical Center | 20 mi |
| Evaluation of Xaluritamig in Adults, Adolescents and Children With Relapsed or Refractory Ewing Sarcoma (EWS) | Phase 1 | Amgen | 20 mi |
| International Rare Histiocytic Disorders Registry (IRHDR) | — | The Hospital for Sick Children | 20 mi |
| Longitudinal Advanced Prostate Cancer Cohort (LAPCC) | — | University of Southern California | 20 mi |
| A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | 20 mi |
| Effects of Using a Storybook, to Explain Leukemia to Children Versus the Standard Child Life Intervention, on Parental Stress. | N/A | Children's Hospital Los Angeles | 20 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | 20 mi |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | Phase 2 | Bio-Path Holdings, Inc. | 20 mi |
| Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies | Phase 1/2 | Corcept Therapeutics | 20 mi |
| Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers | — | University of Southern California | 20 mi |
| Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer | Phase 1 | University of Southern California | 20 mi |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | 20 mi |
| External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | Phase 1/2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| The Multicentre Selective Lymphadenectomy Trial - 3 | N/A | Melanoma Institute Australia | 20 mi |
| Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015) | Phase 2 | Merck Sharp & Dohme LLC | 20 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | 20 mi |
| Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | Phase 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1 | Phase 2 | Healx Limited | 20 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | 20 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | 20 mi |
| Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Innate Pharma | 20 mi |
| Study of SX-682 Plus Enzalutamide in Men With ARPI-Resistant Metastatic Castration Resistant Prostate Cancer | Phase 2 | Syntrix Biosystems, Inc. | 20 mi |
| An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer. | Phase 2 | Jonsson Comprehensive Cancer Center | 20 mi |
| New Approach to Objectively Measure Social Engagement in Older Adults With Hearing Loss | — | University of Southern California | 20 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | 20 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | 20 mi |
| Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems | — | Institut Paoli-Calmettes | 20 mi |
| eMOTION: Examining Affective Mechanisms in Physical Activity Engagement | N/A | University of Southern California | 20 mi |
| A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma | N/A | Alpha Tau Medical LTD. | 20 mi |
| A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours | Phase 1/2 | Ipsen | 20 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | 20 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | 20 mi |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | N/A | University of Colorado, Denver | 20 mi |
| Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes | Phase 2 | Stephen Freedland | 20 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | 20 mi |
| A Study of HC-7366 in Combination With Belzutifan (WELIREG™) in Patients With Renal Cell Carcinoma | Phase 1 | HiberCell, Inc. | 20 mi |
| Pharmacogenomics of Asparaginase Induced Hepatotoxicity | — | University of Southern California | 20 mi |
| Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma | N/A | University of Southern California | 20 mi |
| A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Incyte Corporation | 20 mi |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | Phase 2 | Academic and Community Cancer Research United | 20 mi |
| An Organoid-based Functional Precision Medicine Trial in Osteosarcoma | — | Jonsson Comprehensive Cancer Center | 20 mi |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Phase 1/2 | Qurient Co., Ltd. | 20 mi |
| ERAS-801 for the Treatment of Resectable and Progressive or Recurrent IDH Wildtype Grade IV Glioblastoma or Astrocytoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | Phase 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression | Phase 2 | AbbVie | 20 mi |
| Collection and Storage of Tissue and Blood Samples From Patients With Cancer | — | National Cancer Institute LAO | 20 mi |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | Phase 1/2 | AstraZeneca | 20 mi |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Phase 1/2 | National Cancer Institute (NCI) | 20 mi |
| Losartan + Sunitinib in Treatment of Osteosarcoma | Phase 1 | University of Colorado, Denver | 20 mi |
| A Novel Multiplex ELISA Assay for Surveilling Patients With History of Bladder Cancer | — | Cedars-Sinai Medical Center | 20 mi |
| Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy | Phase 2/3 | Novartis Pharmaceuticals | 20 mi |
| DFC 004 Biomarkers for Active Diabetic Foot Ulcers | — | University of Michigan | 20 mi |
| Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT) | — | M.D. Anderson Cancer Center | 20 mi |
| Continuous Glucose Monitoring in Prediabetes With Health Education Videos | N/A | David S Black, PhD | 20 mi |
| Type 2 Diabetes and Blood Brain Barrier Improvement | Early 1 | University of California, Los Angeles | 20 mi |
| A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. | N/A | Molnlycke Health Care AB | 20 mi |
| New T-UP: Engaging Vulnerable Students in Diabetes Prevention | N/A | University of California, Los Angeles | 20 mi |
| Time Limited Eating in Adolescents With Type 2 Diabetes (KT2D) | N/A | Children's Hospital Los Angeles | 20 mi |
| Transformative Research in Diabetic Nephropathy | — | University of Pennsylvania | 20 mi |
| DETERMINE: Detemir vs NPH | Phase 2 | University of California, Los Angeles | 20 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | 20 mi |
| A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers | N/A | Integra LifeSciences Corporation | 20 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | 20 mi |
| Device Use Reimagined Through Education And Mentorship | N/A | University of California, San Francisco | 20 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | 20 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms | — | Milton S. Hershey Medical Center | 20 mi |
| Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers | N/A | Tides Medical | 20 mi |
| CGM Academy for Youth With Type 1 Diabetes | N/A | Children's Hospital Los Angeles | 20 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | 20 mi |
| Adapting Lifestyle Offloading for DFUs | N/A | University of Southern California | 20 mi |
| Feasibility of a Nutrition Intervention for Patients With Prediabetes at a Federally Qualified Health Center | N/A | Cedars-Sinai Medical Center | 20 mi |
| Designing Team Clinic for Youth With Type 2 Diabetes | — | Children's Hospital Los Angeles | 20 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | 20 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | 20 mi |
| Implementation of Team Clinic for Type 2 Diabetes (TCT2) | N/A | Children's Hospital Los Angeles | 20 mi |
| Type 2 Continuous Glucose Monitoring Academy | N/A | Children's Hospital Los Angeles | 20 mi |
| A Study to Evaluate Pharmacokinetics of LY3209590 in Pediatric Participants With Type 2 Diabetes Mellitus | Phase 1 | Eli Lilly and Company | 20 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | 20 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics | — | Milton S. Hershey Medical Center | 20 mi |
| Assessing Improvements in Mood and Sleep Trial | N/A | University of Pittsburgh | 20 mi |
| Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements | — | Kernel | 20 mi |
| Inflammatory and Glutamatergic Mechanisms of Sustained Threat in Adolescents With Depression | — | University of California, Los Angeles | 20 mi |
| Pain and Major Depressive Disorder | N/A | University of California, Los Angeles | 20 mi |
| In-patient SCC TMS | N/A | University of California, Los Angeles | 20 mi |
| Improving Behavioral Health for Caregivers and Children After Pediatric Injury | N/A | Medical University of South Carolina | 20 mi |
| RCT of Psilocybin-assisted CBT for Depression | Phase 1/2 | University of California, Los Angeles | 20 mi |
| Regulation of Affect and Physiology in Depression | Phase 2 | University of Southern California | 20 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | 20 mi |
| Model-based Electrical Brain Stimulation | N/A | University of Southern California | 20 mi |
| Evaluating tDCS Brain-stimulation in Depression Using MRI | N/A | University of California, Los Angeles | 20 mi |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 20 mi |
| Training Reward Responsiveness Through Virtual Reality | Phase 2 | University of California, Los Angeles | 20 mi |
| Longitudinal Early-onset Alzheimer's Disease Study Protocol | — | Indiana University | 20 mi |
| Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD | Phase 1 | Butler Hospital | 20 mi |
| [18F]PI-2620 Phase 3 Histopathological Study | Phase 3 | Life Molecular Imaging Ltd | 20 mi |
| Polyphenols and Cognitive Decline | N/A | University of California, Los Angeles | 20 mi |
| Deep Repetitive Transcranial Magnetic Stimulation (rTMS) of the Precuneus for Alzheimer Disease (AD) | Phase 1/2 | University of California, Los Angeles | 20 mi |
| Testing & Refinement of CarePair: An Assessment and Referral Platform to Support Family Caregivers of Alzheimer's Disease and Related Dementias. | N/A | University of Southern California | 20 mi |
| Low Intensity Focused Ultrasound for Mild Cognitive Impairment and Mild Alzheimer's Disease | N/A | University of California, Los Angeles | 20 mi |
| Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study | N/A | Cedars-Sinai Medical Center | 20 mi |
| A Dyadic Sleep Health Approach for Persons With Alzheimer's Disease and Caregivers | N/A | University of California, Los Angeles | 20 mi |
| A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue | Phase 2/3 | Pfizer | 20 mi |
| Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC) | — | Cedars-Sinai Medical Center | 20 mi |
| BrainWeighve App Feasibility Study | N/A | University of California, Los Angeles | 20 mi |
| Comparing the Efficacy and Safety of the EndoZip System and Apollo ESG in Obese Patients | N/A | Nitinotes Surgical Ltd. | 20 mi |
| A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients | N/A | University of California, Los Angeles | 20 mi |
| Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy | Phase 2 | Endevica Bio | 20 mi |
| WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy | Phase 2 | Stephen Freedland | 20 mi |
| Benefits of Endoscopic Bariatric Procedures | N/A | Cedars-Sinai Medical Center | 20 mi |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | 20 mi |
| J-Valve Transfemoral Pivotal Study | N/A | JC Medical, Inc., an affiliate of Edwards Lifesciences LLC | 20 mi |
| Heart Attack Research Program- Imaging Study | — | NYU Langone Health | 20 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | 20 mi |
| Diagnostic and Therapeutic Applications of Microarrays in Heart Transplantation | — | University of Alberta | 20 mi |
| Patient-Centered Approach for Treatment Decisions in Mitral Valve Prolapse | — | Northwell Health | 20 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | 20 mi |
| Benefits of Choir for Older Adults With Unaddressed Hearing Loss (WP2) | N/A | Toronto Metropolitan University | 20 mi |
| PARTNER 3 Trial - Aortic Valve-in-Valve | N/A | Edwards Lifesciences | 20 mi |
| Surveillance and Treatment to Prevent Fetal Atrioventricular Block Likely to Occur Quickly (STOP BLOQ) | Phase 3 | NYU Langone Health | 20 mi |
| Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress | Phase 4 | Population Health Research Institute | 20 mi |
| Autus Valve Pivotal Study | N/A | Autus Valve Technologies, Inc. | 20 mi |
| An Early Feasibility Study of the HighLife 28mm Trans-Septal Transcatheter Mitral Valve Replacement System | N/A | HighLife SAS | 20 mi |
| Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients | Phase 2 | Baylor Research Institute | 20 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | 20 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | 20 mi |
| The PIVATAL Study -Study of Ventricular Arrhythmia (VTA) Ablation in Left Ventricular Assist Device (LVAD) Patients | Phase 4 | University of Rochester | 20 mi |
| Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG | Phase 3 | Icahn School of Medicine at Mount Sinai | 20 mi |
| The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves). | N/A | Mayra Guerrero | 20 mi |
| Staged Kidney Transplantation During Combined Heart/Kidney Transplantation | N/A | Cedars-Sinai Medical Center | 20 mi |
| International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | — | SCAD Alliance | 20 mi |
| Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease | N/A | Population Health Research Institute | 20 mi |
| Balloon vs. Self Expanding Transcatheter Valve for Degenerated Bioprosthesis | N/A | Erasmus Medical Center | 20 mi |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. | Phase 4 | Pfizer | 20 mi |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Lexicon Pharmaceuticals | 20 mi |
| Parent Navigator Program (PNP) to Improve Outcomes in Latino/x Children and Parents | N/A | Children's Hospital Los Angeles | 20 mi |
| Development of a Novel Stress Testing Protocol to Define the Relationship Between Coronary Microvascular Dysfunction and Diastology in Women With Angina But No Evidence of Obstructive Coronary Artery Disease | N/A | Cedars-Sinai Medical Center | 20 mi |
| Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women | N/A | Weill Medical College of Cornell University | 20 mi |
| Transcatheter Fontan Stenting: Impact on Hepatic Stiffness and Exercise Capacity | — | Children's Hospital Los Angeles | 20 mi |
| Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US) | N/A | VDyne, Inc. | 20 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | 20 mi |
| Clinical Study of the inQB8 TTVR System | N/A | inQB8 Medical Technologies, LLC | 20 mi |
| AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions | N/A | Boston Scientific Corporation | 20 mi |
| Phase 2/3 Study of KPL-387 in Recurrent Pericarditis | Phase 2/3 | Kiniksa Pharmaceuticals International, plc | 20 mi |
| Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | N/A | Boston Scientific Corporation | 20 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | 20 mi |
| Esophageal Temperature During PVI Using Q-DOT Micro | N/A | Cedars-Sinai Medical Center | 20 mi |
| Cephea Early Feasibility Study | N/A | Abbott Medical Devices | 20 mi |
| Women's Heart Attack Research Program: Stress Ancillary Study | N/A | NYU Langone Health | 20 mi |
| Abbott Vascular Medical Device Registry | — | Abbott Medical Devices | 20 mi |
| Coronary Atherosclerosis T1-Weighted Characterization (CATCH) | N/A | Cedars-Sinai Medical Center | 20 mi |
| Bicuspid Aortic Valve Replacement: Evaluation of Transcatheter Versus Surgery-Pilot Trial | N/A | Cedars-Sinai Medical Center | 20 mi |
| Percutaneous or Surgical Repair In Mitral Prolapse And Regurgitation for ≥60 Year-olds (PRIMARY) | N/A | Annetine Gelijns | 20 mi |
| Cardiac-Control Affecting Learning Through Mindfulness (CALM) | N/A | University of Southern California | 20 mi |
| Cardiac RADIoablation Versus Repeat Catheter Ablation: a Pivotal Randomized Clinical Trial Evaluating Safety and Efficacy for Patients With High-risk Refractory Ventricular Tachycardia (RADIATE-VT) | N/A | Varian, a Siemens Healthineers Company | 20 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | 20 mi |
| WARRIOR Ancillary Study for CCTA Analysis | — | Cedars-Sinai Medical Center | 20 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | 20 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | 20 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | 20 mi |
| Pediatric Prehospital Airway Resuscitation Trial | N/A | Ohio State University | 20 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | 20 mi |
| Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing | — | Cedars-Sinai Medical Center | 20 mi |
| COMPASSION S3 - Evaluation of the SAPIEN 3 Transcatheter Heart Valve in Patients With Pulmonary Valve Dysfunction | N/A | Edwards Lifesciences | 20 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | 20 mi |
| PV Loop & Coarctation Study | — | University of Minnesota | 20 mi |
| CTSN Embolic Protection Trial | N/A | Icahn School of Medicine at Mount Sinai | 20 mi |
| The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C) | N/A | Sunnybrook Health Sciences Centre | 20 mi |
| Using Indoor Air Filtration to Slow Atherothrombosis Progression in Adults With Ischemic Heart Disease History | N/A | University of Southern California | 20 mi |
| WISE CVD - Continuation (WISE HFpEF) | — | Cedars-Sinai Medical Center | 20 mi |
| A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) | Phase 2 | Genentech, Inc. | 20 mi |
| XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP) | N/A | XVIVO Perfusion | 20 mi |
| Effects of Acupuncture on Symptoms of Stable Angina | N/A | University of California, Los Angeles | 20 mi |
| Heart Disease of the Small Arteries in Women and Men | N/A | Cedars-Sinai Medical Center | 20 mi |
| The Cedars-Sinai Smidt Heart Institute Takotsubo Registry & Proteomic Study | — | Cedars-Sinai Medical Center | 20 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation | — | Heart Rhythm Clinical and Research Solutions, LLC | 20 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | 20 mi |
| His-Bundle Corrective Pacing in Heart Failure | N/A | University of Rochester | 20 mi |
| Minima Stent System Post- Approval Study (PAS) | — | Renata Medical | 20 mi |
| Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System | N/A | Aria CV, Inc | 20 mi |
| TVMR With the INNOVALVE System Trial - Early Feasibility Study | N/A | Edwards Lifesciences | 20 mi |
| Outcomes and Health Care Resource Utilization in Pediatric Congenital Heart Disease Patients Undergoing Non-Cardiac Procedures | — | Boston Children's Hospital | 20 mi |
| Trisol System EFS Study | N/A | Trisol Medical | 20 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | 20 mi |
| Thiamine Intervention and Coronary Artery Bypass Grafting | Early 1 | University of California, Los Angeles | 20 mi |
| Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study | N/A | KidSIM Simulation Program | 20 mi |
| PRIMARY Ancillary Substudy | N/A | Annetine Gelijns | 20 mi |
| Bicuspid Aortic Valve Stenosis Transcatheter Aortic Valve Replacement Registry | — | Cedars-Sinai Medical Center | 20 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | 20 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | 20 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | 20 mi |
| The JenaValve ALIGN-AR LVAD Registry | N/A | JenaValve Technology, Inc. | 20 mi |
| Starlight Cardiovascular Lifeline Ductus Arteriosus Stent IDE Study | N/A | Starlight Cardiovascular Inc | 20 mi |
| Artificial Intelligence Guided Echocardiographic Screening of Rare Diseases (EchoNet-Screening) | — | Cedars-Sinai Medical Center | 20 mi |
| CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry | — | Universitätsklinikum Hamburg-Eppendorf | 20 mi |
| TTVR Early Feasibility Study | N/A | Medtronic Cardiovascular | 20 mi |
| AeviceMD for Pediatric Asthma Management | N/A | Irina Dralyuk | 20 mi |
| Using a Smart Inhaler to Support Asthma Management in Adolescents With Intellectual and Developmental Disabilities | N/A | Children's Hospital Los Angeles | 20 mi |
| Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma | Phase 2 | Windward Bio | 20 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | 20 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | 20 mi |
| MDR - Comprehensive Primary Revision Stems PMCF | — | Zimmer Biomet | 20 mi |
| RA-PRO PRAGMATIC TRIAL | Phase 3 | University of Alabama at Birmingham | 20 mi |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | Phase 2/3 | Olatec Therapeutics LLC | 20 mi |
| Biologic Therapy to Prevent Osteoarthritis After ACL Injury | Early 1 | University of California, Los Angeles | 20 mi |
| SMR Stemless Reverse Vs SMR Reverse Shoulder System | N/A | Limacorporate S.p.a | 20 mi |
| A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | Phase 2 | Verona Pharma plc | 20 mi |
| SPIROMICS Study of Early COPD Progression (SOURCE) | — | University of Massachusetts, Worcester | 20 mi |
| Multi-Center Clean Air Randomized Controlled Trial in COPD | Phase 3 | JHSPH Center for Clinical Trials | 20 mi |
| Project 2: Optimizing Engagement and Outcomes in STAND Digital Therapy | N/A | University of California, Los Angeles | 20 mi |
| Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer | Early 1 | Cedars-Sinai Medical Center | 20 mi |
| The Role of Virtual Reality During Regional Anesthesia | N/A | Cedars-Sinai Medical Center | 20 mi |
| Social Support and Enhanced Fear Extinction | N/A | University of California, Los Angeles | 20 mi |
| A Study of NTX-1472 in Social Anxiety Disorder | Phase 2 | Newleos Therapeutics, Inc. | 20 mi |
| HeartGPS: A Study Exploring the Effects of a Psychological Intervention for Parents and Their Babies After Prenatal Cardiac Diagnosis | N/A | Children's Hospital Medical Center, Cincinnati | 20 mi |
| Music-Based Interventions, Aging, Alzheimer's Disease | N/A | University of Southern California | 20 mi |
| Reward Processing and Exposure Therapy for Social Anxiety Disorder | N/A | University of California, Los Angeles | 20 mi |
| Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD) | N/A | University of California, Los Angeles | 20 mi |
| RCT for Latina Mental Health Using Web-Based Apps | N/A | University of California, Los Angeles | 20 mi |
| Virtual Reality vs. Music Relaxation for Reducing Anxiety and Pain During Breast Biopsies | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children | N/A | University of Southern California | 20 mi |
| VR AI Meditation for Pain | N/A | Christopher Almario | 20 mi |
| Intracranial Neurophysiological Signatures of Fear and Anxiety in Humans | N/A | Duke University | 20 mi |
| Resources, Inspiration, Support and Empowerment (RISE) for Black Pregnant Women | Phase 2/3 | Cedars-Sinai Medical Center | 20 mi |
| Very Brief Exposure: Development of a Novel Exposure Modality for Social Anxiety Disorder in Transition-Age Youth | N/A | Children's Hospital Los Angeles | 20 mi |
| Unconscious Reduction of Fear Through Decoded Neuro-Reinforcement | N/A | University of California, Los Angeles | 20 mi |
| Sensory Adapted Dental Environments to Enhance Oral Care for Children With and Without Dental Fear and Anxiety | N/A | University of Southern California | 20 mi |
| Efficacy of Lavender Aromatherapy on Anxiety and Pain Reduction During Awake Otolaryngologic Procedures | N/A | Cedars-Sinai Medical Center | 20 mi |
| Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder | N/A | Adam Frank | 20 mi |
| S.T.A.N.D. Alacrity Center Signature Project | N/A | University of California, Los Angeles | 20 mi |
| Social Support and Reduced Fear Acquisition | N/A | University of California, Los Angeles | 20 mi |
| Evaluation of Neurocognitive Changes in Parkinson's Disease After Low Frequency Burst Stimulation | N/A | University of Southern California | 20 mi |
| A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | BlueRock Therapeutics | 20 mi |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | 20 mi |
| Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Phase 2 | Denali Therapeutics Inc. | 20 mi |
| A Study to Assess Safety and Efficacy of Surgical Implant of RNDP-001 in Patients With Idiopathic Parkinson's Disease | Phase 1/2 | Kenai Therapeutics | 20 mi |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | — | Michael J. Fox Foundation for Parkinson's Research | 20 mi |
| A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | Phase 2/3 | Biohaven Therapeutics Ltd. | 20 mi |
| An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants | Phase 3 | AstraZeneca | 20 mi |
| Treatment of Systemic Lupus Erythematosus (SLE) With N-acetylcysteine | Phase 2 | State University of New York - Upstate Medical University | 20 mi |
| Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease | Phase 3 | NYU Langone Health | 20 mi |
| Study of COYA 302 for the Treatment of ALS | Phase 2 | Coya Therapeutics | 20 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | 20 mi |
| Effect of a Fasting Mimicking Diet on Patients With Multiple Sclerosis (FMDMS) | N/A | University of Southern California | 20 mi |
| MS-ResearchBiomarkerS | — | Cedars-Sinai Medical Center | 20 mi |
| Stopping TSC Onset and Progression 2B: Sirolimus TSC Epilepsy Prevention Study | Phase 2 | Darcy Krueger | 20 mi |
| Central Vein Sign in Multiple Sclerosis Extension Study | N/A | The Cleveland Clinic | 20 mi |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Novartis Pharmaceuticals | 20 mi |
| Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients | Phase 2 | Providence Health & Services | 20 mi |
| Faith in Action! A Church-Based Navigation Model to Increase Breast Cancer Screening in Korean Women | N/A | Cedars-Sinai Medical Center | 20 mi |
| Contrast Enhanced Ultrasound Medical Imaging for Identifying Breast Masses | Phase 1 | University of Southern California | 20 mi |
| Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction | N/A | University of California, Los Angeles | 20 mi |
| Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer | Phase 2 | University of Texas Southwestern Medical Center | 20 mi |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Phase 1 | Alterome Therapeutics, Inc. | 20 mi |
| Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies | Phase 1/2 | AstraZeneca | 20 mi |
| Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer | Phase 1/2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Ivermectin in Combination With Balstilimab or Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer | Phase 1/2 | Yuan Yuan | 20 mi |
| Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment | — | MiraKind | 20 mi |
| A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies | Phase 1/2 | AtlasMedx, Incorporated | 20 mi |
| Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery | N/A | University of Southern California | 20 mi |
| A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | Phase 1/2 | Gilead Sciences | 20 mi |
| (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Phase 2 | Atossa Therapeutics, Inc. | 20 mi |
| Breast Cancer Screening Adherence for Women at Moderate Risk for Breast Cancer | — | University of Southern California | 20 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | 20 mi |
| IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases | Phase 2 | Alice Chung | 20 mi |
| A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors | Phase 1/2 | Marengo Therapeutics, Inc. | 20 mi |
| Study of 68Ga-R10602 | Phase 1 | Radionetics Oncology | 20 mi |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | 20 mi |
| Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC | Phase 2 | Reshma L. Mahtani, D.O. | 20 mi |
| Gene Therapy for HER-Positive Cancer (SENTRY-HER2) | Phase 1/2 | Vironexis Biotherapeutics Inc. | 20 mi |
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) | Phase 1/2 | University of Southern California | 20 mi |
| Converting HR+ Breast Cancer Into an Individualized Vaccine | Phase 2 | Weill Medical College of Cornell University | 20 mi |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Phase 2 | Processa Pharmaceuticals | 20 mi |
| A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients | Phase 4 | Jonsson Comprehensive Cancer Center | 20 mi |
| Breast Cancer Survivorship Biorepository | — | University of Southern California | 20 mi |
| Project SOAR (Speaking Our African American Realities) Awakenings for Black American Women Diagnosed With Breast Cancer | N/A | University of California, Los Angeles | 20 mi |
| Access to Genetic Testing in Underserved Patients With Cancer | N/A | University of Southern California | 20 mi |
| Core Biopsies for Establishing a Breast Tumor Tissue Repository | — | University of Southern California | 20 mi |
| SDM POSSIBLE: A Breast Cancer Treatment Decision Aid for Women 70+ With Low-Risk Stage I Breast Cancers | N/A | Beth Israel Deaconess Medical Center | 20 mi |
| ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | 20 mi |
| A Study of Breast Cancer Risk Factors and Outcomes of People in Florida | — | Memorial Sloan Kettering Cancer Center | 20 mi |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors | — | University of Southern California | 20 mi |
| DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE) | Phase 2 | Criterium, Inc. | 20 mi |
| FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer | Phase 1 | Regor Pharmaceuticals Inc. | 20 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | 20 mi |
| Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and Other Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | 20 mi |
| Brain Health in Breast Cancer Survivors | — | Jonsson Comprehensive Cancer Center | 20 mi |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Phase 1 | OncoNano Medicine, Inc. | 20 mi |
| A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults With HR+ Breast Cancer and Other Select Solid Tumors | Phase 1 | Totus Medicines | 20 mi |
| Increasing Germline Genetic Testing for Patients With Cancer | N/A | Josh Peterson | 20 mi |
| To Study the Effect of Inavolisib in Combination With Fulvestrant in Participants With Breast Cancer | Phase 2 | Hoffmann-La Roche | 20 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | 20 mi |
| Mobile Application to Improve Health-Related Outcomes in Patients With Advanced Lung Cancer | N/A | Massachusetts General Hospital | 20 mi |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | Iovance Biotherapeutics, Inc. | 20 mi |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | 20 mi |
| Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | Phase 1/2 | Neonc Technologies, Inc. | 20 mi |
| Gilteritinib for the Treatment of ALK NSCLC | Phase 1 | University of Michigan Rogel Cancer Center | 20 mi |
| Qualitative Study on Detection & Tx of NSCLC in Pts w/ a History of Alcohol or SUD | — | University of Southern California | 20 mi |
| A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | Phase 1/2 | Verastem, Inc. | 20 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | 20 mi |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | OSE Immunotherapeutics | 20 mi |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Phase 1/2 | Obsidian Therapeutics, Inc. | 20 mi |
| Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab | Phase 1/2 | Linnaeus Therapeutics, Inc. | 20 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | 20 mi |
| A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors | Phase 1/2 | Alentis Therapeutics AG | 20 mi |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | 20 mi |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | 20 mi |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Phase 1 | Pfizer | 20 mi |
| Testing the Safety of Dapagliflozin Prior to Surgery for the Treatment of Patients With Stage IA Lung Adenocarcinoma | Early 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | Shanghai Junshi Bioscience Co., Ltd. | 20 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. | Phase 1 | Bristol-Myers Squibb | 20 mi |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | Phase 2 | Amgen | 20 mi |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Phase 1 | Amgen | 20 mi |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | 20 mi |
| Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | Phase 1 | RayzeBio, Inc. | 20 mi |
| An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | Phase 1/2 | Jonsson Comprehensive Cancer Center | 20 mi |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Phase 1 | Bicara Therapeutics | 20 mi |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | 20 mi |
| Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | Phase 1/2 | Genprex, Inc. | 20 mi |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Phase 1/2 | Iovance Biotherapeutics, Inc. | 20 mi |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Phase 2 | Boehringer Ingelheim | 20 mi |
| Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | Phase 3 | Nuvation Bio Inc. | 20 mi |
| A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | 20 mi |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | Phase 1 | Anusha Kalbasi | 20 mi |
| A Study of NX-1607 in Adults With Advanced Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 20 mi |
| Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors | Phase 1 | SystImmune Inc. | 20 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | 20 mi |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | 20 mi |
| A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201) | Phase 2 | Amgen | 20 mi |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Phase 2 | Apollomics Inc. | 20 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | 20 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | 20 mi |
| Observational Lung Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform | — | Elephas | 20 mi |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | 20 mi |
| Adapting and Testing a Novel Self-Compassion Intervention to Reduce Lung Cancer Stigma | N/A | Loyola Marymount University | 20 mi |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Phase 1/2 | Daiichi Sankyo | 20 mi |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | 20 mi |
| A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | Mersana Therapeutics | 20 mi |
| S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Phase 1/2 | Servier Bio-Innovation LLC | 20 mi |
| A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification | Phase 1 | BeiGene | 20 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Phase 3 | Merck Sharp & Dohme LLC | 20 mi |
| Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation | Phase 1/2 | RedCloud Bio | 20 mi |
| Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | 20 mi |
| A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | Phase 1/2 | LigaChem Biosciences, Inc. | 20 mi |
| Volrustomig Priming Regimens Exploratory Phase II Platform Study | Phase 2 | AstraZeneca | 20 mi |
| A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors | Phase 1 | Bristol-Myers Squibb | 20 mi |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas | Phase 1 | EvolveImmune United, Inc | 20 mi |
| A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | 20 mi |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Phase 1 | Novartis Pharmaceuticals | 20 mi |
| MRI and Biomarkers for Lung Nodules Detected During Lung Cancer Screening | — | Cedars-Sinai Medical Center | 20 mi |
| TT-10 (PORT-6) and TT-4 (PORT-7) as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors | Phase 1/2 | Portage Biotech | 20 mi |
| Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308) | Phase 1 | Amgen | 20 mi |
| Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | Phase 2 | CatalYm GmbH | 20 mi |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | Phase 2 | AstraZeneca | 20 mi |
| SMP-3124LP in Adults With Advanced Solid Tumors | Phase 1/2 | Sumitomo Pharma America, Inc. | 20 mi |
| A Study of MT-4561 in Patients With Various Advanced Solid Tumors | Phase 1/2 | Tanabe Pharma America, Inc. | 20 mi |
| Utilizing Advocates and Supporters to Increase Lung Cancer Screening Rates in Eligible Participants | N/A | Jonsson Comprehensive Cancer Center | 20 mi |
| SW-682 in Advanced Solid Tumors | Phase 1 | SpringWorks Therapeutics, Inc. | 20 mi |
| A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors | Phase 1/2 | Bayer | 20 mi |
| A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies | Phase 1 | RasCal Therapeutics, Inc. | 20 mi |
| A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies | Phase 1/2 | GV20 Therapeutics | 20 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 20 mi |
| A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | 20 mi |
| Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | Phase 3 | Zydus Therapeutics Inc. | 20 mi |
| DILIN - Prospective Study | — | Duke University | 20 mi |
| Long-term, Open-label Study of SAR447537 (INBRX-101) in Adults With Alpha-1 Antitrypsin Deficiency Emphysema | Phase 2 | Sanofi | 20 mi |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 20 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | 20 mi |
| CM for Patients With ALD After Liver Transplant | N/A | Arpan A. Patel, MD | 20 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | 20 mi |
| SAMe Trial for Patients With Alcoholic Cirrhosis | Phase 2 | Indiana University | 20 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | 20 mi |
| Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND) | Phase 3 | Mirum Pharmaceuticals, Inc. | 20 mi |
| PiMZ Longitudinal Cohort (PiMZ Logic) | — | Columbia University | 20 mi |
| A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment | — | Ipsen | 20 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | 20 mi |
| A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1 | Regeneron Pharmaceuticals | 20 mi |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | Gilead Sciences | 20 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | 20 mi |
| Genetic Collection Protocol | — | Arbor Research Collaborative for Health | 20 mi |
| Longitudinal Study of the Porphyrias | — | Icahn School of Medicine at Mount Sinai | 20 mi |
| Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial | — | Prime Medicine, Inc. | 20 mi |
| Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Phase 3 | Takeda | 20 mi |
| TReatment for ImmUne Mediated PathopHysiology | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 20 mi |
| Drug-Induced Liver Injury (DILI) Network Retrospective | — | Duke University | 20 mi |
| Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients | — | University of California, Los Angeles | 20 mi |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | 20 mi |
| An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency | Phase 1/2 | iECURE, Inc. | 20 mi |
| A Prospective Database of Infants With Cholestasis | — | Arbor Research Collaborative for Health | 20 mi |
| Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US) | — | Mirum Pharmaceuticals, Inc. | 20 mi |
| Primary Sclerosing Cholangitis in Children | — | Arbor Research Collaborative for Health | 20 mi |
| Danazol for Treatment of Cytopenias in Patients With Cirrhosis | Phase 2 | University of Southern California | 20 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | 20 mi |
| National Liver Cancer Screening Trial | Phase 4 | University of Texas Southwestern Medical Center | 20 mi |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | 20 mi |
| Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations | Phase 1 | Tyra Biosciences, Inc | 20 mi |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | 20 mi |
| AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease | Phase 1 | University of Southern California | 20 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | 20 mi |
| Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma | Phase 1 | Nammi Therapeutics Inc | 20 mi |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers | Phase 1 | Jonsson Comprehensive Cancer Center | 20 mi |
| Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | N/A | Cedars-Sinai Medical Center | 20 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | 20 mi |
| Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases | Phase 2 | Kamya Sankar | 20 mi |
| A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer | Phase 2 | AstraZeneca | 20 mi |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | 20 mi |
| First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours | Phase 1/2 | AstraZeneca | 20 mi |
| Multilevel Determinants of Socioeconomic Disparities in Geographic Late-Stage Hepatocellular Carcinoma Hotspots | — | University of Southern California | 20 mi |
| A Study of MGC026 in Participants With Advanced Solid Tumors | Phase 1 | MacroGenics | 20 mi |
| SIRT With Tremelimumab and Durvalumab for Resectable HCC | Phase 1 | Jiping Wang, MD, PhD | 20 mi |
| Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions | Phase 1/2 | Thomas Advanced Medical LLC | 21 mi |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Phase 2 | Eli Lilly and Company | 21 mi |
| Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: | — | Supernus Pharmaceuticals, Inc. | 22 mi |
| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Phase 2 | Janssen Pharmaceutica N.V., Belgium | 22 mi |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Phase 1/2 | Eikon Therapeutics | 22 mi |
| Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | Phase 2 | NMD Pharma A/S | 22 mi |
| Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | Phase 1/2 | CJ Bioscience, Inc. | 22 mi |
| Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma | Phase 2 | City of Hope Medical Center | 22 mi |
| Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors | N/A | City of Hope Medical Center | 22 mi |
| A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1/2 | AstraZeneca | 22 mi |
| A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes | Phase 1 | GluBio Therapeutics Inc. | 22 mi |
| A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | Phase 2 | Hoag Memorial Hospital Presbyterian | 22 mi |
| A Biobehavioral Intervention to Reduce Adverse Outcomes in Young Adult Testicular Cancer Survivors | N/A | University of California, Irvine | 22 mi |
| Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | 22 mi |
| Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma | Phase 2 | University of California, San Diego | 22 mi |
| A Biobehavioral Intervention for Latino/Hispanic Young Adults with Cancer | N/A | University of California, Irvine | 22 mi |
| SELVA: A Phase 3 Study Evaluating QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Microcystic Lymphatic Malformations | Phase 3 | Palvella Therapeutics, Inc. | 22 mi |
| Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell Cancer | Phase 1 | City of Hope Medical Center | 22 mi |
| Study With [225Ac]Ac-FL-020 in mCRPC Participants | Phase 1 | Full-Life Technologies GmbH | 22 mi |
| A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | Phase 1/2 | BeOne Medicines | 22 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) Amyloidosis | Phase 1 | Janssen Research & Development, LLC | 22 mi |
| ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Phase 1/2 | Adagene Inc | 22 mi |
| Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies | N/A | University of Colorado, Denver | 22 mi |
| A Phase 2 Study of Leronlimab in Combination With TAS-102 + Bevacizumab in Previously Treated Participants With mCRC | Phase 2 | CytoDyn, Inc. | 22 mi |
| Nemtabrutinib With Rituximab for the Treatment of Patients With Mantle Cell Lymphoma | Phase 2 | City of Hope Medical Center | 22 mi |
| Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation | Phase 2 | SWOG Cancer Research Network | 22 mi |
| PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer | Phase 2 | Hoag Memorial Hospital Presbyterian | 22 mi |
| Daily Adaptive Radiation Therapy Using an Individualized Approach for Prostate Cancer | N/A | Varian, a Siemens Healthineers Company | 22 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | 22 mi |
| AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | 22 mi |
| A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer | Phase 2 | Toray Industries, Inc | 22 mi |
| A Phase I Trial of 61Cu-NODAGA-PSMA for Patients with Prostate Cancer | Phase 1 | Hoag Memorial Hospital Presbyterian | 22 mi |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Phase 1 | Nuvalent Inc. | 22 mi |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL | Phase 2 | Prescient Therapeutics, Ltd. | 22 mi |
| A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer | Phase 4 | Coherus Oncology, Inc. | 22 mi |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | Phase 2 | National Cancer Institute (NCI) | 22 mi |
| Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers | Phase 2 | NRG Oncology | 22 mi |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Loxo Oncology, Inc. | 22 mi |
| Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma | N/A | Christopher Zachary | 22 mi |
| The iLet Experience Study | — | Beta Bionics, Inc. | 22 mi |
| HOPE Intervention for Fitness | N/A | University of California, Irvine | 22 mi |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 22 mi |
| Positive Affect Treatment for Adolescents with Early Life Adversity | N/A | University of California, Irvine | 22 mi |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Phase 2 | Merck Sharp & Dohme LLC | 22 mi |
| Biomarker Exploration in Aging, Cognition and Neurodegeneration | Phase 3 | University of California, Irvine | 22 mi |
| Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass | N/A | Boston Scientific Corporation | 22 mi |
| CardiolRx in Recurrent Pericarditis Following IL-1 Blocker Cessation | Phase 3 | Cardiol Therapeutics Inc. | 22 mi |
| VenusP-Valve Pivotal Study (PROTEUS STUDY) | N/A | Venus MedTech (HangZhou) Inc. | 22 mi |
| TTVR STRONG Under Coverage With Evidence Development (CED) Study | — | Edwards Lifesciences | 22 mi |
| Evaluating the Effect of Adipose Tissue Processed With the SyntrFuge™ System for Knee Osteoarthritis | N/A | Syntr Health Technologies, Inc. | 22 mi |
| A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | Phase 2 | Eli Lilly and Company | 22 mi |
| Zimmer Biomet Shoulder Arthroplasty PMCF | N/A | Zimmer Biomet | 22 mi |
| Different Types of Massage Therapy to Reduce Anxiety During Chemotherapy Infusion in Patients With Cancer | N/A | City of Hope Medical Center | 22 mi |
| Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting | N/A | City of Hope Medical Center | 22 mi |
| Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | 22 mi |
| A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | Phase 2 | AskBio Inc | 22 mi |
| A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 22 mi |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Phase 1/2 | Apollo Therapeutics Ltd | 22 mi |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | 22 mi |
| Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer | Phase 2 | City of Hope Medical Center | 22 mi |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | 22 mi |
| Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | Phase 2 | City of Hope Medical Center | 22 mi |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | Phase 1/2 | National Cancer Institute (NCI) | 22 mi |
| A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | Phase 1/2 | BlossomHill Therapeutics | 22 mi |
| A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | Phase 1/2 | AstraZeneca | 22 mi |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | 22 mi |
| Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors | Phase 1/2 | AstraZeneca | 22 mi |
| Empathic Communication Skills (ECS) Training | N/A | Memorial Sloan Kettering Cancer Center | 22 mi |
| Photon Craniospinal Irradiation for the Treatment of Leptomeningeal Disease Secondary to Breast Cancer or Non-small Cell Lung Cancer | Phase 2 | City of Hope Medical Center | 22 mi |
| Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | Phase 1 | Amgen | 22 mi |
| Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer | Phase 1 | City of Hope Medical Center | 22 mi |
| Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer | Phase 3 | Canadian Cancer Trials Group | 22 mi |
| Study of XB010 in Subjects With Solid Tumors | Phase 1 | Exelixis | 22 mi |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | Phase 1 | AstraZeneca | 22 mi |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Phase 1/2 | Tango Therapeutics, Inc. | 22 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | 22 mi |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors | Phase 1 | AbbVie | 22 mi |
| First in Human Study of AZD9592 in Solid Tumors | Phase 1 | AstraZeneca | 22 mi |
| Study of S-606001 as an Add-on to Enzyme Replacement Therapy (ERT) in Participants With Late-onset Pompe Disease (LOPD) | Phase 2 | Shionogi | 22 mi |
| Hepatitis C Tracker Study | N/A | University of Southern California | 23 mi |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | Phase 2 | VA Office of Research and Development | 23 mi |
| A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss | Phase 2 | VA Office of Research and Development | 23 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | 23 mi |
| Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study | — | VA Office of Research and Development | 23 mi |
| Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc | Phase 2 | VA Office of Research and Development | 23 mi |
| Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis | Phase 4 | VA Office of Research and Development | 23 mi |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Phase 3 | TransThera Sciences (Nanjing), Inc. | 24 mi |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Phase 3 | AVEO Pharmaceuticals, Inc. | 24 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | 24 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | 24 mi |
| Personalized Brain Stimulation to Treat Chronic Concussive Symptoms | Phase 2 | University of California, Los Angeles | 24 mi |
| A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | Phase 2 | Pfizer | 24 mi |
| A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine | Phase 2 | Boehringer Ingelheim | 24 mi |
| A Phase 1, First-in-human Study of OKN4395 and Pembrolizumab in Patients With Solid Tumors | Phase 1 | Epkin | 24 mi |
| ELUCIDATE FFRct Study | — | Elucid Bioimaging Inc. | 24 mi |
| A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | Context Therapeutics Inc. | 24 mi |
| Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | 24 mi |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Phase 3 | GlaxoSmithKline | 24 mi |
| PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Pyrotech Therapeutics, Inc. | 24 mi |
| A Study of sEphB4-HSA in Kaposi Sarcoma | Phase 2 | Vasgene Therapeutics, Inc | 24 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor | Phase 1 | Abbisko Therapeutics Co, Ltd | 24 mi |
| A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | Phase 2 | Vantage Biosciences Ltd | 24 mi |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | 24 mi |
| Analysis of Lumbar Spine Stenosis Specimens for Identification of Transthyretin Cardiac Amyloidosis | — | Columbia University | 24 mi |
| Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Knee Osteoarthritis | Early 1 | R3 Medical Research | 24 mi |
| Safety and Feasibility of Umbilical Cord Wharton's Jelly Allograft Injections for Lumbar Pain | Phase 1 | R3 Stem Cell | 24 mi |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | Phase 2 | Ventus Therapeutics U.S., Inc. | 24 mi |
| Lupus Landmark Study: A Prospective Registry and Biorepository | — | Lupus Research Alliance | 24 mi |
| Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer | Phase 3 | Relay Therapeutics, Inc. | 24 mi |
| A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | Phase 1 | MBQ Pharma | 24 mi |
| Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | Phase 1/2 | Strand Therapeutics Inc. | 24 mi |
| A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer | Phase 1/2 | BioNTech SE | 24 mi |
| A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer | Phase 1 | Abbisko Therapeutics Co, Ltd | 24 mi |
| Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases | Phase 1 | Kiromic BioPharma Inc. | 24 mi |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Phase 1/2 | Krystal Biotech, Inc. | 24 mi |
| A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | Phase 3 | Merck Sharp & Dohme LLC | 24 mi |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune Inc. | 24 mi |
| A Study of Venetoclax in Combination With Isatuximab and Dexamethasone for Relapsed/Refractory Multiple Myeloma | Phase 2 | Oncotherapeutics | 24 mi |
| A Study of AZD3470, a PRMT5 Inhibitor, in Patients With MTAP Deficient Advanced/Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | 24 mi |
| Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma | Early 1 | Oncotherapeutics | 24 mi |
| A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma | Phase 2 | C4 Therapeutics, Inc. | 24 mi |
| Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical) | Phase 3 | AstraZeneca | 24 mi |
| A Trial of Selinexor, Ruxolitinib and Methylprednisolone | Phase 1 | Oncotherapeutics | 24 mi |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | Phase 3 | Sanofi | 24 mi |
| Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators | N/A | Cedars-Sinai Medical Center | 24 mi |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Hoffmann-La Roche | 24 mi |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Phase 3 | Definium Therapeutics US, Inc. | 24 mi |
| Talimogene Laherparepvec, Nivolumab and Trabectedin for Sarcoma | Phase 2 | Sarcoma Oncology Research Center, LLC | 24 mi |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | Phase 1/2 | Regeneron Pharmaceuticals | 24 mi |
| Pembrolizumab and Pemetrexed for Progressive Chordoma | Phase 2 | Saint John's Cancer Institute | 24 mi |
| Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors | Phase 1 | Trethera | 24 mi |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Phase 1 | Boehringer Ingelheim | 24 mi |
| A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 2 | Novartis Pharmaceuticals | 24 mi |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | Phase 1/2 | Merck Sharp & Dohme LLC | 24 mi |
| SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma | Phase 1/2 | Sarcoma Oncology Research Center, LLC | 24 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | 24 mi |
| A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | 24 mi |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Phase 1 | Astellas Pharma Inc | 24 mi |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Karyopharm Therapeutics Inc | 24 mi |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase 1/2 | Takeda | 24 mi |
| A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | Phase 1 | Sun Pharma Advanced Research Company Limited | 24 mi |
| Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Phase 1/2 | Pyxis Oncology, Inc | 24 mi |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Parabilis Medicines, Inc. | 24 mi |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Phase 3 | Acrotech Biopharma Inc. | 24 mi |
| Study for AZD4360 in Participants With Advanced Solid Tumours | Phase 1/2 | AstraZeneca | 24 mi |
| BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Phase 1/2 | Bold Therapeutics, Inc. | 24 mi |
| Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | Phase 2 | Northwestern University | 24 mi |
| A Study of Pembrolizumab+ sEphB4 in Metastatic Urothelial Carcinoma | Phase 2 | Vasgene Therapeutics, Inc | 24 mi |
| Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors | Phase 1 | Riboscience, LLC. | 24 mi |
| A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors | Phase 2 | EpicentRx, Inc. | 24 mi |
| GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma | Phase 2 | Sarcoma Oncology Research Center, LLC | 24 mi |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | 24 mi |
| Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) | Phase 2 | AstraZeneca | 24 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | 24 mi |
| Metastatic Leiomyosarcoma Biomarker Protocol | — | University of Michigan Rogel Cancer Center | 24 mi |
| A Study of ADRX-0405 in Subjects With Select Advanced Solid Tumors | Phase 1 | Adcentrx Therapeutics | 24 mi |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | 24 mi |
| Urine Metabolites in the Diagnosis of Disease | — | Luventix, Inc. | 24 mi |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Phase 1 | Arcus Biosciences, Inc. | 24 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | 24 mi |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | 24 mi |
| An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | Phase 2 | Novartis Pharmaceuticals | 24 mi |
| Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors | Phase 2/3 | Vasgene Therapeutics, Inc | 24 mi |
| Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma | Phase 2 | Sarcoma Oncology Research Center, LLC | 24 mi |
| Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors | Phase 1 | ImmunoGenesis | 24 mi |
| Transition to KPL-387 Monotherapy Dosing & Administration Study | Phase 2 | Kiniksa Pharmaceuticals International, plc | 24 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | 24 mi |
| A Global Study Comparing Pulsed Field Ablation With Electrographic Flow Mapping Versus Posterior Wall Ablation for Persistent Atrial Fibrillation | N/A | Boston Scientific Corporation | 24 mi |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) | Phase 1 | UCB Biopharma SRL | 24 mi |
| The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis | N/A | University of Colorado, Denver | 24 mi |
| Genicular Artery Embolization Vs Observation for Symptomatic Knee Osteoarthritis | N/A | University of California, Los Angeles | 24 mi |
| Treat-to-Target Serum Urate Versus Treat-to-Avoid Symptoms in Gout | Phase 4 | Massachusetts General Hospital | 24 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | MoonLake Immunotherapeutics AG | 24 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Phase 3 | Definium Therapeutics US, Inc. | 24 mi |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Phase 2 | Sanofi | 24 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | 24 mi |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Phase 1 | Senhwa Biosciences, Inc. | 24 mi |
| Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer | — | Saint John's Cancer Institute | 24 mi |
| Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) | Phase 2 | Merck Sharp & Dohme LLC | 24 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 24 mi |
| A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer | Phase 1/2 | BriaCell Therapeutics Corporation | 24 mi |
| Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer | Phase 3 | Laekna Limited | 24 mi |
| Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | 24 mi |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | 24 mi |
| Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | 24 mi |
| A Beta-only IL-2 ImmunoTherapY Study | Phase 1/2 | Medicenna Therapeutics, Inc. | 24 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | 24 mi |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | 24 mi |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | 24 mi |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | Phase 1/2 | EMD Serono Research & Development Institute, Inc. | 24 mi |
| A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AstraZeneca | 24 mi |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 24 mi |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | 24 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | 24 mi |
| Study of GS-0272 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | 26 mi |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) | — | Janssen Research & Development, LLC | 26 mi |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Takeda | 26 mi |
| Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | — | BeiGene | 26 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Phase 3 | AstraZeneca | 26 mi |
| A Study to Evaluate the Efficacy and Safety of TL118 in Solid Tumors Patients | Phase 2 | Teligene US | 26 mi |
| A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of Creatinine in a Non Interventional Cohort | Phase 1 | AstraZeneca | 26 mi |
| Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | Phase 1 | Merck Sharp & Dohme LLC | 26 mi |
| Open-Label Extension Protocol to SNK01-AD01 Study | Phase 2 | NKGen Biotech, Inc. | 26 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Women | Phase 3 | Weill Medical College of Cornell University | 26 mi |
| REvascularization CHoices Among Under-Represented Groups Evaluation: The RECHARGE Trial - Minorities | Phase 3 | Weill Medical College of Cornell University | 26 mi |
| Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and Adult Patients With SLE and RA | Phase 1 | Neutrolis | 26 mi |
| Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ | N/A | Glendale Adventist Medical Center d/b/a Adventist Health Glendale | 26 mi |
| Study to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 2 | Teligene US | 26 mi |
| A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | Phase 2 | Teligene US | 26 mi |
| A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma | Phase 1/2 | Hoffmann-La Roche | 26 mi |
| Restoring Facial Volume After GLP-1 Weight Loss With Radiesse | Phase 4 | Kalpna Kay Durairaj, MD, FACS | 26 mi |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | 26 mi |
| Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure | Phase 3 | Pharmacosmos A/S | 26 mi |
| Filipino Family Health Initiative 1.0 | N/A | Kaiser Permanente | 26 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | 26 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | 26 mi |
| Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | Phase 3 | Rapamycin Holdings Inc. | 27 mi |
| Efficacy and Safety of KAI-9531 in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes | Phase 3 | Kailera | 28 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | 28 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | Phase 3 | Takeda | 28 mi |
| At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study] | N/A | SecondWave Systems Inc. | 28 mi |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | 28 mi |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer | Phase 3 | Canadian Cancer Trials Group | 28 mi |
| Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy | Phase 3 | City of Hope Medical Center | 28 mi |
| Telemedicine for Improvement of Care for Older Adults With Cancer in the Underserved Community, The GAIN-S Trial | N/A | City of Hope Medical Center | 28 mi |
| Total Marrow and Lymphoid Irradiation Before Donor Transplant and Cyclophosphamide in Treating Patients With Acute Myeloid Leukemia | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma | Phase 1/2 | Cyclacel Pharmaceuticals, Inc. | 28 mi |
| FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1/2 | Janssen Research & Development, LLC | 28 mi |
| PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV) | Phase 2 | Pulmotect, Inc. | 28 mi |
| Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of Revumenib and Mezigdomide in People With Leukemia | Phase 1/2 | Memorial Sloan Kettering Cancer Center | 28 mi |
| Pembrolizumab and Decitabine With or Without Venetoclax in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | 28 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | 28 mi |
| Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Phase 2 | MeiraGTx, LLC | 28 mi |
| Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases | Phase 1 | City of Hope Medical Center | 28 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | 28 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | 28 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | 28 mi |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma | Phase 1 | City of Hope Medical Center | 28 mi |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | Phase 1 | Stelexis BioSciences | 28 mi |
| Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy | Phase 1 | Norman J. Lacayo | 28 mi |
| First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 | Bayer | 28 mi |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | Phase 2 | City of Hope Medical Center | 28 mi |
| Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy | Phase 3 | City of Hope Medical Center | 28 mi |
| Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | Phase 1/2 | City of Hope Medical Center | 28 mi |
| A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases | Phase 3 | Rakuten Medical, Inc. | 28 mi |
| Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R) | Phase 2 | City of Hope Medical Center | 28 mi |
| Telehealth Intervention for Ostomy Self-Management | Phase 2 | City of Hope Medical Center | 28 mi |
| Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer | Phase 2 | AbbVie | 28 mi |
| GCC19CART for Patients With Metastatic Colorectal Cancer | Phase 1 | Lyell Immunopharma, Inc. | 28 mi |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Xencor, Inc. | 28 mi |
| IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase 2 | Fred Hutchinson Cancer Center | 28 mi |
| Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of Carmustine With and Without Ethanol in Subjects With Lymphoma | Phase 2 | VIVUS LLC | 28 mi |
| Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma | Phase 1 | AIDS Malignancy Consortium | 28 mi |
| Phase 1, Open-label, Dose-escalation Trial with CD38-SADA:177 Lu-DOTA Drug Complex in Subjects with Relapsed or Refractory Non-Hodgkin Lymphoma | Phase 1 | Y-mAbs Therapeutics | 28 mi |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Phase 1/2 | Corbus Pharmaceuticals Inc. | 28 mi |
| This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma | Phase 1 | LTZ Therapeutics, Inc. | 28 mi |
| A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | AbbVie | 28 mi |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | City of Hope Medical Center | 28 mi |
| BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL | Phase 1 | PeproMene Bio, Inc. | 28 mi |
| PSCA-Targeting CAR-T Cells Plus or Minus Radiation for the Treatment of Patients With PSCA+ Metastatic Castration-Resistant Prostate Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| Prostate Cancer Screening for People at Genetic Risk for Aggressive Disease, PATROL Study | — | University of Washington | 28 mi |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | 28 mi |
| Evaluation of DNA Methylation Signatures for the Diagnosis and Management of Thyroid Nodules | N/A | City of Hope Medical Center | 28 mi |
| Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation | Phase 2 | City of Hope Medical Center | 28 mi |
| Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma | Phase 1 | Marker Therapeutics, Inc. | 28 mi |
| Risk Assessment Evaluation for Identifying Participants at High Risk for Stomach Cancer | N/A | City of Hope Medical Center | 28 mi |
| [18F]-rhPSMA PET-CT Imaging Performance in Patients With Prostate Cancer | N/A | City of Hope Medical Center | 28 mi |
| Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | Phase 1 | Ascentage Pharma Group Inc. | 28 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | 28 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | 28 mi |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome | — | Stanford University | 28 mi |
| Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules | — | City of Hope Medical Center | 28 mi |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | 28 mi |
| Intracranial Genetically Modified Immune Cells (TGFβR2KO/IL13Rα2 CAR T-Cells) for the Treatment of Recurrent or Progressive Glioblastoma or Grade 3 or 4 IDH-Mutant Astrocytoma | Phase 1 | City of Hope Medical Center | 28 mi |
| Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors | Phase 1 | City of Hope Medical Center | 28 mi |
| Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of BG-C477 in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 28 mi |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | Phase 1/2 | BioInvent International AB | 28 mi |
| A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | Phase 1/2 | Debiopharm International SA | 28 mi |
| Phase 1b/2a Randomized Double-blind Study to Investigate Safety Tolerability PK PD Preliminary Efficacy of Oral Administration of SNIPR001 in Patients With Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplant Receiving FQ Prophylaxis & Harboring FQR Ecoli Pre-Transplant | Phase 1/2 | SNIPR Biome Aps. | 28 mi |
| Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | Phase 2 | City of Hope Medical Center | 28 mi |
| Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma | Phase 2 | City of Hope Medical Center | 28 mi |
| Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy for Recurrent Epithelial Ovarian Cancer | Phase 1 | PhotonPharma, Inc. | 28 mi |
| Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer | Phase 1/2 | Recursion Pharmaceuticals Inc. | 28 mi |
| Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma | Phase 1 | SIRPant Immunotherapeutics, Inc. | 28 mi |
| External Beam Radiation Therapy in Combination With Talquetamab for the Treatment of Multiple Myeloma Patients With Extramedullary Disease | Phase 1/2 | City of Hope Medical Center | 28 mi |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Phase 1 | Janssen Research & Development, LLC | 28 mi |
| 8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | City of Hope Medical Center | 28 mi |
| Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors | Phase 2 | Children's Hospital of Philadelphia | 28 mi |
| Primary Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | Phase 3 | The Netherlands Cancer Institute | 28 mi |
| CBM588 Capsules in Combination With Nivolumab and Ipilimumab for the Treatment of Advanced Stage Kidney Cancer | Phase 1 | Osel, Inc. | 28 mi |
| Prospective Data Registry and Quality of Life Assessment of Patients Undergoing Radiotherapy With the RefleXion Medical Radiotherapy System | — | RefleXion Medical | 28 mi |
| PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| Evaluation of Bridging Radiation Therapy Before CAR T-Cell Infusion for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma | Early 1 | City of Hope Medical Center | 28 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | 28 mi |
| Safety of MT-401-OTS in Patients With Relapsed AML or MDS | Phase 1 | Marker Therapeutics, Inc. | 28 mi |
| Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma | Phase 1 | City of Hope Medical Center | 28 mi |
| A Global Study of the PETAL Consortium | — | Massachusetts General Hospital | 28 mi |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | Phase 1/2 | AstraZeneca | 28 mi |
| Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning | Phase 2 | City of Hope Medical Center | 28 mi |
| Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia | Early 1 | City of Hope Medical Center | 28 mi |
| Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Nerviano Medical Sciences | 28 mi |
| 177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Phase 1/2 | Alliance Foundation Trials, LLC. | 28 mi |
| MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | City of Hope Medical Center | 28 mi |
| Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals | Phase 2 | Fred Hutchinson Cancer Center | 28 mi |
| A Study of CHS-114 in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors | Phase 1 | Coherus Oncology, Inc. | 28 mi |
| Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome | Phase 1 | City of Hope Medical Center | 28 mi |
| A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors | Phase 1 | Proviva Therapeutics, Inc. | 28 mi |
| Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma | Phase 1 | National Cancer Institute (NCI) | 28 mi |
| A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome | Phase 1 | Edgewood Oncology Inc. | 28 mi |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Phase 1/2 | Bristol-Myers Squibb | 28 mi |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | Phase 1/2 | BlueSphere Bio, Inc | 28 mi |
| Liquid Biopsy for Early Detection of Colorectal Cancer Using Circular RNA | — | City of Hope Medical Center | 28 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) | Phase 1 | Hoffmann-La Roche | 28 mi |
| Modified Immune Cells (CD19 CAR T Cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma | Phase 2 | City of Hope Medical Center | 28 mi |
| Venetoclax and a Pediatric-Inspired Regimen for the Treatment of Newly Diagnosed B Cell Acute Lymphoblastic Leukemia | Phase 1 | City of Hope Medical Center | 28 mi |
| Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | Phase 1 | City of Hope Medical Center | 28 mi |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Jazz Pharmaceuticals | 28 mi |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Phase 1/2 | Dren Bio | 28 mi |
| Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC | — | City of Hope Medical Center | 28 mi |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Phase 1 | Orca Biosystems, Inc. | 28 mi |
| An Exosomal microRNA Signature for Preoperative Staging in Colon Cancer | — | City of Hope Medical Center | 28 mi |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | 28 mi |
| A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | City of Hope Medical Center | 28 mi |
| IL13Ra2-CAR T Cells With or Without Nivolumab and Ipilimumab in Treating Patients With GBM | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Phase 1 | Syndax Pharmaceuticals | 28 mi |
| Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome | Phase 1 | City of Hope Medical Center | 28 mi |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | Phase 1/2 | Ossium Health, Inc. | 28 mi |
| Gemcitabine and Leflunomide in Patients With Advanced Unresectable Pancreatic Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | Phase 2 | GOG Foundation | 28 mi |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 28 mi |
| Modified Immune Cells (TAG72-CAR T Cells) for the Treatment of Patients With Platinum Resistant Epithelial Ovarian Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | — | City of Hope Medical Center | 28 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | 28 mi |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma | Phase 1 | AstraZeneca | 28 mi |
| A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia | Phase 1 | Crossbow Therapeutics, Inc. | 28 mi |
| Nab-Paclitaxel PIPAC in Combination With Paclitaxel and Ramucirumab for the Treatment of Stomach Cancer With Peritoneal Metastases | Phase 1 | City of Hope Medical Center | 28 mi |
| Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis | Phase 1 | National Cancer Institute (NCI) | 28 mi |
| Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study | Phase 2 | City of Hope Medical Center | 28 mi |
| cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer | — | City of Hope Medical Center | 28 mi |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | 28 mi |
| A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies | Phase 1 | Umoja Biopharma | 28 mi |
| Light Therapy and Occupational Therapy Fatigue Management-Based Intervention for Patients With Genitourinary Cancers | N/A | City of Hope Medical Center | 28 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 28 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | Phase 1/2 | Hoffmann-La Roche | 28 mi |
| Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | Phase 2 | Rahul Aggarwal | 28 mi |
| Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Phase 1 | TScan Therapeutics, Inc. | 28 mi |
| Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | Phase 2 | University of Miami | 28 mi |
| Time-Restricted Eating Versus Nutritional Counseling for the Reduction of Radiation or Chemoradiation Tx Side Effects in Patients With Prostate, Cervical, or Rectal Cancers | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 28 mi |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | 28 mi |
| Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients | Phase 3 | University of California, San Diego | 28 mi |
| A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies | Phase 1 | Incyte Corporation | 28 mi |
| Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer | — | City of Hope Medical Center | 28 mi |
| CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia | Phase 1 | City of Hope Medical Center | 28 mi |
| Mezigdomide (CC-92480) Post Idecabtagene Vicleucel in Treating Patients With Relapsed Multiple Myeloma | Phase 1 | City of Hope Medical Center | 28 mi |
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | Phase 2 | Matthew Galsky | 28 mi |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | Phase 1 | Celgene | 28 mi |
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Phase 1 | Auron Therapeutics, Inc. | 28 mi |
| Treatment Recommendations for Gastrointestinal Cancers Via Large Language Models | N/A | Chinese Academy of Sciences | 28 mi |
| Early Onset Colorectal Cancer Detection | — | City of Hope Medical Center | 28 mi |
| Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors | N/A | City of Hope Medical Center | 28 mi |
| Study to Detect Changes in Urinary and Gut Microbiome During Androgen Deprivation Therapy and Radiation Therapy in Patients With Prostate Cancer | — | City of Hope Medical Center | 28 mi |
| SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | Phase 1 | Dana-Farber Cancer Institute | 28 mi |
| 225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | Phase 1 | Nectin Therapeutics Ltd | 28 mi |
| Provider-Mediated Communication of Genetic Testing Results to At-Risk Relatives of Cancer Patients to Improve Genetic Counseling and Testing Rates, Family HOPE Study | N/A | City of Hope Medical Center | 28 mi |
| Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | Phase 1 | City of Hope Medical Center | 28 mi |
| Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant | Phase 1 | City of Hope Medical Center | 28 mi |
| The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation | Phase 1/2 | National Cancer Institute (NCI) | 28 mi |
| Multi-modality Imaging and Collection of Biospecimen Samples in Understanding Bone Marrow Changes in Patients With Acute Myeloid Leukemia Undergoing TBI and Chemotherapy | Early 1 | City of Hope Medical Center | 28 mi |
| Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome | Phase 2 | City of Hope Medical Center | 28 mi |
| Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR) | Phase 1 | City of Hope Medical Center | 28 mi |
| Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma | Phase 2/3 | Privo Technologies | 28 mi |
| Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | Phase 1/2 | City of Hope Medical Center | 28 mi |
| Venetoclax + Azacitidine vs. Induction Chemotherapy in AML | Phase 2 | Massachusetts General Hospital | 28 mi |
| Actinium 225 Labeled Anti-CEA Antibody (Ac225-DOTA-M5A) for the Treatment of CEA Producing Advanced or Metastatic Cancers | Phase 1 | City of Hope Medical Center | 28 mi |
| Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2) | Phase 2 | I-Mab Biopharma US Limited | 28 mi |
| Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the Treatment of Biliary Tract Cancer Patients With Peritoneal Metastases | Phase 1 | City of Hope Medical Center | 28 mi |
| Leflunomide in Combination With Steroids for the Treatment of Acute Graft-versus-Host Disease After Donor Stem Cell Transplant for Hematologic Malignancies | Phase 1 | City of Hope Medical Center | 28 mi |
| MMRC Horizon One Adaptive Platform Trial Evaluating Therapies in RRMM | Phase 2 | Multiple Myeloma Research Consortium | 28 mi |
| An Investigational Scan (64Cu-Labeled M5A Antibody) in Combination With SOC Chemotherapy and Radiotherapy in Locally Advanced Rectal Cancer | Early 1 | City of Hope Medical Center | 28 mi |
| Study of REM-422 in Patients With AML or Higher Risk MDS | Phase 1 | Remix Therapeutics | 28 mi |
| Prediction of Neoadjuvant Chemotherapy Response in Pancreatic Cancer | — | City of Hope Medical Center | 28 mi |
| Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | 28 mi |
| A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) | Phase 1/2 | Regeneron Pharmaceuticals | 28 mi |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of BGB-11417 in Participants With Myeloid Malignancies | Phase 1/2 | BeiGene | 28 mi |
| Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL | Phase 1/2 | Amgen | 28 mi |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Phase 2 | University of Michigan Rogel Cancer Center | 28 mi |
| A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer | Phase 1/2 | Pfizer | 28 mi |
| Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Phase 3 | Surgimab | 28 mi |
| Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant | Phase 1 | City of Hope Medical Center | 28 mi |
| Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Positive B-Cell Acute Lymphoblastic Leukemia | Phase 1 | City of Hope Medical Center | 28 mi |
| Papaverine in Combination With Radiation Therapy for the Treatment of Locally Advanced Rectal Cancer, DINOMITE Trial | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | 28 mi |
| Oral Cryotherapy to Decrease Taste Changes in Prostate Cancer Patients Receiving Taxane Chemotherapy | N/A | City of Hope Medical Center | 28 mi |
| Detection of Minimal Residual Disease Using Exosomal miRNA Distant Metastasis Markers | — | City of Hope Medical Center | 28 mi |
| Quality of Life in Cutaneous Lymphoma Patients Using the Skindex29 | — | City of Hope Medical Center | 28 mi |
| A Phase 1 Study of IM-1021 in Participants With Advanced Cancer | Phase 1 | Immunome, Inc. | 28 mi |
| CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma | Phase 1 | City of Hope Medical Center | 28 mi |
| Splicing-based Predictive Learning for Individual Chemotherapy Evaluation in Colorectal Cancer | — | City of Hope Medical Center | 28 mi |
| Denosumab for Type 1 Diabetes | Phase 1/2 | City of Hope Medical Center | 28 mi |
| A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | GentiBio, Inc | 28 mi |
| Circulating Biomarkers in the Development of Type 1 Diabetes | — | City of Hope Medical Center | 28 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | 28 mi |
| Improving Islet Transplantation Outcomes With Gastrin for Type I Diabetes | Phase 1/2 | City of Hope Medical Center | 28 mi |
| Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy | Phase 2 | City of Hope Medical Center | 28 mi |
| Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT Trial | Phase 2 | City of Hope Medical Center | 28 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | 28 mi |
| Virtual Reality Interventions for the Improvement of Depression, Anxiety and Pain in Patients With Head and Neck Cancer and Caregivers | N/A | City of Hope Medical Center | 28 mi |
| Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial | Phase 2 | City of Hope Medical Center | 28 mi |
| Effects of White Button Mushroom on Inflammation in Obese Postmenopausal Women at High Risk of Breast Cancer | N/A | City of Hope Medical Center | 28 mi |
| An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis | Phase 4 | City of Hope Medical Center | 28 mi |
| A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 2 | Bayer | 28 mi |
| Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors | N/A | Novian Health Inc. | 28 mi |
| Study of Zelenectide Pevedotin in Participants With Advanced Breast Cancer | Phase 2 | BicycleTx Limited | 28 mi |
| Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) | Phase 1 | Minerva Biotechnologies Corporation | 28 mi |
| High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | 28 mi |
| Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer | Phase 2 | National Cancer Institute (NCI) | 28 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | 28 mi |
| A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs | Phase 1 | Mabwell (Shanghai) Bioscience Co., Ltd. | 28 mi |
| Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. | Phase 2 | City of Hope Medical Center | 28 mi |
| Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | Phase 1 | Janux Therapeutics | 28 mi |
| AOH1996 for the Treatment of Refractory Solid Tumors | Phase 1 | City of Hope Medical Center | 28 mi |
| cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | — | Adela, Inc | 28 mi |
| Evaluation of Geriatric Assessment and Management for Older Adults With Non-small Cell Lung Cancer Receiving Chemotherapy Radiation Therapy | N/A | City of Hope Medical Center | 28 mi |
| KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01) | — | Merck Sharp & Dohme LLC | 28 mi |
| Phase II Trial of Lung Chemoemobolization | Phase 2 | City of Hope Medical Center | 28 mi |
| KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | Phase 1/2 | Merck Sharp & Dohme LLC | 28 mi |
| Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer | Phase 1 | Ohio State University Comprehensive Cancer Center | 28 mi |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 28 mi |
| A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | Phase 1 | Pfizer | 28 mi |
| A Vaccine Booster (GEO-CM04S1) for the Prevention of COVID-19 in Patients With Chronic Lymphocytic Leukemia | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. | Phase 2 | Taiho Oncology, Inc. | 28 mi |
| A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | Phase 3 | Taiho Oncology, Inc. | 28 mi |
| GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2 | Phase 1 | Y-mAbs Therapeutics | 28 mi |
| Positron Emission Tomography (PET) Guided Stereotactic Body Radiation Therapy for the Treatment of Oligoprogressive Non-small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma | Phase 2 | City of Hope Medical Center | 28 mi |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | 28 mi |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | AstraZeneca | 28 mi |
| Prevention of GvHD in Participants With Hematological Malignancies Undergoing Hematopoietic Stem Cell Transplant (HSCT) | Phase 1 | Tr1X, Inc. | 28 mi |
| Feasibility of Cell-Free DNA Liquid Biopsy in Screening High-Risk Patients for Lung Cancer | N/A | City of Hope Medical Center | 28 mi |
| A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) | Phase 1/2 | Phanes Therapeutics | 28 mi |
| Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer | Phase 1 | City of Hope Medical Center | 28 mi |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | Daiichi Sankyo | 28 mi |
| Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers | N/A | City of Hope Medical Center | 28 mi |
| Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC), Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors, Receiving Intravenous (IV) Infusion of Azirkitug (ABBV-514) Alone or in Combination With Budigalimab or Bevacizumab | Phase 1 | AbbVie | 28 mi |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | 28 mi |
| Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma | Phase 2 | City of Hope Medical Center | 28 mi |
| AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors | Phase 1 | Amgen | 28 mi |
| A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma | — | City of Hope Medical Center | 28 mi |
| An Exosomal miRNA-based Liquid Biopsy for ICC Detection | — | City of Hope Medical Center | 28 mi |
| Exosome-derived Extrahepatic Metastasis Detection By Liquid Biopsy In Colorectal Cancer Liver Metastases | — | City of Hope Medical Center | 28 mi |
| A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer | — | City of Hope Medical Center | 28 mi |
| Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Breast Cancer | Phase 2 | City of Hope Medical Center | 28 mi |
| T-Cell Therapy (ECT204) in Adults With Advanced HCC | Phase 1/2 | Eureka Therapeutics Inc. | 28 mi |
| An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer | — | City of Hope Medical Center | 28 mi |
| Liquid Biopsy Using Exosomal miRNA Enables Risk Stratification of Potential Metastasis in Patients With Intrahepatic Cholangiocarcinoma. | — | City of Hope Medical Center | 28 mi |
| Lynch Syndrome X-Talk of Enteral Mucosa With Immune System | — | San Raffaele University | 28 mi |
| Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma | — | City of Hope Medical Center | 28 mi |
| Stage II/III Colorectal Cancer Recurrence | — | City of Hope Medical Center | 28 mi |
| Early Detection of Advanced Adenomas and Colorectal Cancer | — | City of Hope Medical Center | 28 mi |
| Exactech Shoulder Post Market Clinical Follow-up Study | — | Exactech | 29 mi |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | Genmab | 29 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | 29 mi |
| Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | — | Alliance for Clinical Trials in Oncology | 29 mi |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | 29 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 29 mi |
| Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | — | ECOG-ACRIN Cancer Research Group | 29 mi |
| Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer | N/A | Alliance for Clinical Trials in Oncology | 29 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | 29 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 29 mi |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | Phase 3 | SWOG Cancer Research Network | 29 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | 29 mi |
| Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. | Phase 4 | Royal Biologics | 29 mi |
| Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | Phase 3 | Merck Sharp & Dohme LLC | 29 mi |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Phase 3 | Merck Sharp & Dohme LLC | 29 mi |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Phase 2 | National Cancer Institute (NCI) | 29 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | 29 mi |
| TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer | N/A | Linda Chan, MD | 30 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | 30 mi |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 | VistaGen Therapeutics, Inc. | 30 mi |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Hoffmann-La Roche | 30 mi |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Phase 1 | Amgen | 30 mi |
| A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | Phase 2 | TrueBinding, Inc. | 30 mi |
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Phase 3 | Cerevance | 30 mi |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Phase 4 | Impax Laboratories, LLC | 30 mi |
| Mindful Self-Compassion to Address PTSD and Substance Use in Unhoused Women | N/A | University of California, Los Angeles | 32 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Phase 2 | Novo Nordisk A/S | 32 mi |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | Phase 2 | AstraZeneca | 32 mi |
| The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System | N/A | May Health | 32 mi |
| Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | 32 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | 32 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | 33 mi |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Phase 2 | T. John Winhusen, PhD | 35 mi |
| Entire-body PET Scans for Multiple Sclerosis | Early 1 | Brain Health Alliance | 35 mi |
| GATE-251 or Placebo for the Reduction of Symptoms of Major Depressive Disorder With Comorbid Anxiety and Insomnia | Phase 2 | Syndeio Biosciences, Inc | 36 mi |
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Phase 1 | X4 Pharmaceuticals | 36 mi |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | 37 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes | Phase 3 | Kailera | 37 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Phase 3 | Kailera | 37 mi |
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | Phase 3 | Lipocine Inc. | 38 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | Phase 3 | MoonLake Immunotherapeutics AG | 39 mi |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Phase 2 | Kymera Therapeutics, Inc. | 39 mi |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Phase 2 | Incyte Corporation | 39 mi |
| A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | Phase 2 | Hoffmann-La Roche | 39 mi |
| Customized TULSA-PRO Ablation Registry | — | Profound Medical Inc. | 39 mi |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Phase 3 | Generate Biomedicines | 39 mi |
| Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing Disease | Phase 2 | University of Washington | 40 mi |
| AVEIR DR Coverage With Evidence Development (CED) Study | — | Abbott Medical Devices | 40 mi |
| Aveir AR Coverage With Evidence Development (CED) Study | — | Abbott Medical Devices | 40 mi |
| Aveir VR Real-World Evidence Post-Approval Study | — | Abbott Medical Devices | 40 mi |
| Aveir VR Coverage With Evidence Development Post-Approval Study | — | Abbott Medical Devices | 40 mi |
| Aveir DR Real-World Evidence Post-Approval Study | — | Abbott Medical Devices | 40 mi |
| Dehydrated Human Amnion Membrane and Standard of Care Versus Standard of Care Alone in Nonhealing Diabetic Foot Ulcers | N/A | Axolotl Biologix | 46 mi |
| EFS of the DUO System for Tricuspid Regurgitation | N/A | CroiValve Limited | 46 mi |
| An Early Feasibility Study Evaluation of an Implant Free Interatrial Shunt to Improve Heart Failure | N/A | InterShunt Technologies, Inc. | 46 mi |
| Abbott Cephea Mitral Valve Disease Registry | — | Abbott Medical Devices | 46 mi |
| AltaValve Pivotal Trial | N/A | 4C Medical Technologies, Inc. | 46 mi |
| EFS of the CardioMech MVRS | N/A | CardioMech AS | 46 mi |
| ULTRA-HFIB-Redo: Ultrasound-based Renal Sympathetic Denervation vs Control in Redo Ablation Patients | N/A | Vivek Reddy | 46 mi |
| Innoventric Trillium™ Stent Graft Early Feasibility Study (EFS) | N/A | Innoventric LTD | 46 mi |
| A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | Phase 3 | Eli Lilly and Company | 47 mi |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | Phase 2 | Ascletis Pharma (China) Co., Limited | 48 mi |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | Eli Lilly and Company | 48 mi |
| California MEPS Hub | N/A | University of California, Los Angeles | 48 mi |